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ABSTRACT 
 
 
In vitro Assembly of an Infectious cDNA Clone of Infectious Bronchitis Virus  
and Its Application as a Gene Transfer Vector. (December 2003) 
Soonjeon Youn, B.S.; M.S.; D. V. M., Konkuk University 
Chair of Advisory Committee: Dr. Ellen W. Collisson 
 
 
An infectious cDNA clone of Vero cell adapted Beaudette strain of IBV was 
constructed using in vitro assembly of cDNA fragments. The entire genome of IBV was 
RT-PCR amplified into seven fragments, with each piece overlapping about 10 
nucleotides. The fragments were ligated and transcribed to synthesize RNA, which was 
transfected into BHK-21 cells. These cells were then overlaid onto IBV susceptible Vero 
cells. After five days transfection, the virus was successfully rescued from the 
transfected cells. The cDNA clone from our laboratory strain has a five nucleotide 
insertion not present in the originally sequenced virus, resulting in total genome size of 
27,613 nucleotides. The infectious cDNA clone was further manipulated to demonstrate 
its potential as a gene transfer vector, by replacing the ORF5a open reading frame with 
enhanced green fluorescent protein. The recombinant infectious cDNA clone was also 
successfully rescued after three days transfection of BHK-21 cells followed by co-
culturing with Vero cells. This study showed that the 5a protein, whose function is not 
known, is not necessary for in vitro IBV replication. This study also showed that the 5a 
ORF is a good candidate for an insertion site of recombinant genes for the development 
of IBV infectious cDNA clone as a gene transfer vector. 
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CHAPTER I 
 
INTRODUCTION 
 
INFECTIOUS BRONCHITIS  
 Avian infectious bronchitis is one of the most important poultry diseases in the 
world, causing great economic losses to the poultry industry (39). It is also considered 
the most common disease in both broilers and layers. Its causative agent is infectious 
bronchitis virus (IBV). IBV was first described in 1931 by Schalk and Hawn in North 
Dakota as an “apparently new respiratory disease of baby chicks” (158) and then 
subsequently isolated by Beaudette and Hudson in 1937 (14). Initially IBV caused 
respiratory disease in chickens but later additional types of IBV emerged. IBV can be 
divided into three different forms based on the primary symptoms in infected birds. The 
respiratory form of IBV primarily results in respiratory illness such as gasping, tracheal 
rales, coughing and nasal discharge (6). This form is caused by IBV strains that include 
Massachusetts, Arkansas, and Connecticut. Second is the nephropathogenic form of 
IBV, which causes not only respiratory illness but also causes nephritis by certain stains 
of IBV such as Gray, Holts, Australian T strain and PA/Wolg/98 (1, 208). Often the 
respiratory form is more severe in young chicks and the nephritic form is predominantly 
seen in older chicks up to 10 weeks of age. The third form of IBV is a reproductive form  
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in which the virus directly affects the reproductive organs of birds such as ovaries and 
reproductive tracts (41). The reproductive form of IBV infection causes not only poor 
egg production in infected birds but also poor egg quality. The most economically 
detrimental consequences for the poultry industry of infection of IBV are poor egg 
quality and markedly poor growth in chicks that survive causing vast economic loss in 
the poultry industry (14). Chicks infected with IBV show varying mortality depending 
on strains of virus that infect flocks, illness ranges from asymptomatic infection to very 
high mortality with no lesions because of rapid disease progression (39). A problem in 
controlling of IBV is the increased susceptibility to bacterial infection, such as E. coli 
and this complication exacerbating chronic respiratory disease and airsacculitis (6). 
 The incubation time of the virus is dose dependent and ranges from 18 to 36 
hours after transmission by inhalation. The virus is not vertically transmitted through 
eggs (39). In experimental infection studies, IBV can be isolated from the trachea, lungs, 
kidney, and bursa of chickens from 24 hr to the 7th day after aerosol exposure (76). 
 The control of IBV depends mainly on vaccination. However, concurrent 
infection of the flocks with more than one serotype and vaccine breaks by field strains 
differing from the vaccine have been reported. With live vaccines, it may be possible to 
prevent disease but not prevent infection (65, 87). Usually a vaccine regimen requires 
using an inactived IBV strain given as an oil-in-water emulsion to chickens that have 
already been primed by vaccination with a live attenuated IBV vaccine.  
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CLASSIFICATION  
Avian infectious bronchitis virus is a member of the Coronaviridae family that 
belongs to the order of Nidovirales. Nidovirales contains four families, the Toroviridae, 
Arteriviridae, Roniviridae as well as Coronaviridae (34, 168). The classification is based 
on polycistronic genome organization and regulation of gene expression from a nested 
set of subgenomic mRNAs, despite significant size differences between genuses ranging 
from 13 to 32 kb. Coronaviruses, as well as the other nidoviruses, have a unique, 
discontinuous transcription strategy that produces several subgenomic mRNAs, as well 
as the genomic RNA packaged into its virions. The subgenomic mRNAs form 3’ co-
terminal nested sets in which each mRNA contains a common 3’ untranslated region and 
5’ leader sequence (90). 
Coronaviruses infect various animal species, causing respiratory, gastrointestinal, 
cardiovascular, and neurological disease (126). Human coronaviruses have been 
associated with mild common colds, diarrhea, possibly multiple sclerosis, as well as 
severe acute respiratory syndrome (SARS) (70). Coronaviruses have been divided into 
three distinct groups by antigenic cross-reactivity and sequence analysis of structural 
protein genes. Group I coronaviruses include human coronavirus 229E (HCoV-229E), 
transmissible gastroenteritis virus (TGEV), canine coronavirus (CCV), feline 
coronavirus (FECV), and feline infectious peritonitis virus (FIPV). Group II includes 
human coronavirus OC43 (HCoV-OC43), murine hepatitis virus (MHV), and bovine 
coronavirus (BoCV). Group III includes IBV with some turkey coronaviruses (TCV) and 
pheasant coronavirus. The recently identified coronavirus that is the causative agent of 
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severe acute respiratory syndrome (SARS) in humans is distinct from other 
coronaviruses based on its genomic organization and structural genes (186). However, 
there was a report that SARS is a Group II coronaviruses based on phylogenetic study 
comparing the replicase gene with other coronaviruses and torovirus (167). 
 
MOLECULAR BIOLOGY OF CORONAVIRUS 
Morphology 
Coronavirus virions are pleomorphic in shape with a diameter of 80 to 160 nm and 
are composed of four major structural proteins, which include the nucleocapsid protein 
(N), the integral membrane protein (M), the spike protein (S) and the small envelope 
protein (E) (90). Petal-like spikes that appear as a corona give the virus its name and 
have a distinct morphology by electron microscopy (EM) (15). These prominent surface 
projections of up to 20 nm in length cover the entire virion surface (15). Some species of 
coronaviruses, such as TCV, have smaller spikes on the virion surface. The N proteins 
interact with viral genomic RNA to form helical ribonucleoprotein complexes (RNP) 
that are similar in morphology to paramyxovirus RNPs (49). Not only genomic RNA but 
also every subgenomic RNA interacts with N protein forming RNP in the infected cells. 
In the case of TGEV, an icosahedral core shell structure has been shown by EM (142). 
One report indicated that two different forms of IBV virions could be made in infected 
cells (119). One form is the infectious virus particle, which has viral RNP, the other 
form has a lower density and has no RNP. This finding is consistent with the observation 
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that co-expression of E and M protein produce virus like particles (VLPs) without 
internal virion structures (193).  
 
Genome Organization 
The genomes of the coronaviruses ranging from 27.6 to 32 kb are the largest 
genomes of all the known RNA viruses. Coronaviruses have a linear, positive sensed 
polyadenylated RNA that is infectious when transfected into susceptible cells (112, 161). 
In infected cells, coronaviruses produce from five to eight subgenomic RNAs in addition 
to genomic RNA depending on the virus (165). Each RNA is numbered according to its 
size. Genomic and subgenomic RNA organization of IBV is illustrated in Figure 1. IBV 
has six subgenomic RNAs including its genomic RNA with RNA 1 being the largest, 
and RNA 6 being the smallest (35). The genomic RNA, as well as every subgenomic 
RNA, is 5’ end capped and has a polyadenylated tail of about 100 nucleotides (nts) at the 
3’ end (112, 113, 161, 196). Subgenomic RNAs range from 2 to 8 kb and with genomic 
RNA share a common 3’ terminus forming a nested set (172, 173). Genomic and 
subgenomic RNAs have 3’ and 5’ untranslated regions (UTR) believed to contain cis-
signal sequences for viral replication and transcription (48). The 5’ end of each mRNA 
has leader sequence about 60 to 72 nts (91, 92, 171). Most coronavirus ORFs are 
preceded by an untranslated region of varying length containing a conserved sequence, 
which has been given the term intergenic sequence (IG) or transcription regulatory 
sequence (TRS) (28, 90). 
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FIG. 1. Schematic of the IBV genomic and subgenomic RNA organization. S represents the 
spike glycoprotein; M, the membrane protein; E, the small envelope protein; N, the 
nucleocapsid protein. RNA1 encodes replicase gene, pp1a and pp1ab; RNA2 encodes S 
protein, RNA3 encodes 3a, 3b and the E proteins, RNA4 encodes the M protein, RNA5 
encodes 5a and 5b whose functions are not known and RNA6 encodes the N protein. The 
black box represents poly (A) tails.  
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The overall IBV genome organization is similar to other prototype coronaviruses such as 
MHV and TGEV, having the “replicase gene-S-E-M-N” gene order. ORFs encoding 
small nonstructural group specific proteins, such as 3a, b and 5a, b of IBV lie between 
the structural genes (103). Comparisons of the different genomic organizations of 
coronaviruses are illustrated in Figure 2. However, with a smaller genome size of 27.6 
kb compare to other coronaviruses, such as MHV with a genome of 31 kb, IBV genomic 
usage is more compact. ORFs of IBV are overlapped. For example, the 3’ end of the 1b 
genome overlaps with the S ORF by about 50 nts (30). 
IBV RNA 1, which encodes the replicase gene, is indistinguishable from 
genomic RNA and contains the ORF for replicase genes, pp1a and pp1ab, and ORFs for 
the structural proteins. Like most coronaviruses, every subgenomic RNA of IBV only 
expresses the extreme 5’ ORF except for RNA 3 and RNA 5, which encode 3a, 3b, 3c 
(E), 5a and 5b ORFs respectively. IBV has several nonstructural proteins of which 
functions are not well understood. The exception is gene 3c, which encodes an important 
structural membrane protein, E protein (104, 203). Two thirds of RNA 1, about 20 kb, of 
IBV genome encoding two large ORF1a and 1b, that express polyproteins of pp1a, 441 
kDa and pp1b, 300 kDa, respectively. pp1ab is produced via -1 ribosomal frame shifting 
upstream of a psuedoknot structure between ORF1a and ORF1b (25, 26). Polyproteins 
encoded by gene 1 are cleaved by viral proteinases during posttranslational processing 
(57). 
 RNA 2 encodes the spike (S) protein of IBV. As mentioned previously, the 3’ 
end of 1b ORF overlaps with the ORF of S by about 50 nts in the Beaudette strain. It is  
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FIG 2. Comparison of genome organization of coronaviruses. ORF1a and 
ORF1b are interrupted and shortened to highlight the remaining genes. Boxes 
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not certain if this is a common feature of IBV. RNA 3 encodes three ORFs, 3a, 3b, and 
3c. Nucleotide sequencing and expression studies indicated that gene 3 was tricistronic 
and that ORF3a and 3b produced proteins in small amounts in IBV infected cells (103), 
but their functions are a subject of further study. The ORF3c encodes the small envelope 
protein (103, 104). An unusual folding region (UFR) of 265 nts containing the 3a and 3b 
coding region upstream of the E ORFs was noticed (95). This UFR consists of five RNA 
stem-loops that could be modeled into a superstructure by the interaction of two putative 
pseudoknots. It was predicted that this region could serve as an internal ribosomal entry 
site (IRES) for the cap independent expression of E protein. RNA 4 of IBV encodes M 
protein. Just as RNA 3 is multicistronic, nucleotide sequencing and expression studies 
showed that RNA 5 is dicistronic and encodes two nonstructural proteins, 5a and 5b. 
Expression of these two proteins has been shown in IBV infected cells, but the function 
of these proteins and mechanism of expression also needs to be determined (105). 
RNA6, the smallest but the most abundant RNA in IBV infected cells encodes the N 
proteins.  
 
Coronavirus Non-Structural Proteins 
 RNA 1 encodes the coronavirus replicase gene. The schematic of genomic RNA 
organization of coronaviruses is illustrated in Figure 3. The replicase genes of 
coronaviruses consist of two large open reading frames, ORF1a and ORF1b, the latter of 
which is expressed by ribosomal frame shifting (26). The ORF1a and ORF1ab 
translation products are large nonstructural polyproteins encoding polyproteins pp1a and  
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FIG. 3. Schematic of coronavirus gene 1 organization. PL1 pro represents a papain-like 
proteinase 1; PL2 pro, a papain-like proteinase 2; 3CLpro, a 3C-like proteinase; MP1 and 
MP2 represent the hydrophobic domains; RdRp, RNA-dependent RNA polymerase; 
HEL, helicase and the black box indicates a domain with an unknown function in 
coronaviruses. The small green box between RdRp and HEL represent a cysteine-rich 
domain. IBV and SCoV have only one PL2 pro domain instead of two PL pro. 
HD 
RdRp 
HD
3CLpro
ORF 1a                
HEL 
HD
x
PL1pro      PL2pro 
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pp1ab, respectively. Polyprotein precursors of the nidovirus ORF1a and ORF1ab 
translation products are cleaved by viral proteinases at a minimum of 13 sites (207). 
ORF1b encodes RNA dependent RNA polymerase (RdRp), helicase (HEL) and 
methyltransferase (56). Functions of the ORF1a-encoded polyproteins include 
proteinases that process viral nonstructural proteins and proteins that are membrane 
associated (100-102, 133). Most nidovirus replicase subunits are thought to assemble 
into an RNA-protein complex, which is presumably held together by protein-protein and 
/or protein-RNA interactions. Some of replicase genes have been shown to co-localize 
with viral RNA (19, 20, 133, 159, 164, 192). Putative hydrophobic domains in the 
ORF1a protein have been proposed to mediate the membrane association of this 
complex (19, 164). The N terminal half of the ORF1a protein encodes multiple papain-
like cysteine protease domains (PLpro). The proteolytic activity of PLpro has been 
demonstrated and characterized in detail (73, 97, 99, 207). Compared to group I and 
group II coronaviruses that encode two PLpro, IBV has two overlapping PLpro and only 
the first PLpro is functional. SARS also encodes only one PL2pro (97, 186). Another 
functional coronaviral proteinase, the 3C-like cysteine protease (3CLpro) is located in the 
central region of the ORF 1a polyprotein (114). This 3CLpro belongs to the 
chymotrypsin-like protease superfamily and is flanked by hydrophobic domains (207). 
Proteolytic activity of the protein has been demonstrated and characterized in detail in 
MHV, HCoV and IBV (69, 74, 115, 206). Several studies have shown that this 
proteinase cleaves pp1ab fusion polyprotein at the QS dipeptide bonds to the 100-kDa 
protein species in IBV (101, 102, 107). 
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Compared to other positive strand RNA viruses, distinct features of a coronavirus 
replicase include a helicase domain downstream of the RdRp motif in ORF1b and the 
classic GDD core motif in the RdRp is substituted by an SDD (68). In addition, 
compared to a putative catalytic triad, such as cysteine, histidine and glutamic acid, for 
the proteinase activity, cysteine and histidine are sufficient enough for coronavirus 
3CLpro protease activity (102).  
 
Coronavirus Structural Proteins 
Coronaviruses have four essential structural proteins. These include spike 
glycoprotein (S), small envelope protein (E), integral membrane protein (M), and 
nucleocapsid protein (N). In addition to these elements, some strains of group I and II 
coronaviruses have an additional glycoprotein, the hemagglutinin/esterase (HE) protein 
which is assumed to be acquired from influenza virus C and is not essential for viral 
replication in vivo or in vitro (4, 16, 37, 119). 
The S protein is the most prominent virion protein that can be seen by EM, forming a 
corona around the virions. This type I glycoprotein passes through the host derived lipid 
bilayer membrane once, with most of the molecule forming an amino-terminal 
ectodomain (18). The S protein can be divided into three different parts other than the 
signal sequence that targets the proteins to the ER (117). The first part is the ectodomain 
of S, which is largely exposed outer surface of the virion. The second part is the 
transmembrane domain (TM), which consists of hydrophobic amino acids that are 
embedded in the virus envelope. The third part of the S protein is the endodomain that 
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has a C terminal tail inside of the virions. The TM and endodomain are believed to 
confer the stability of the S proteins on the virion.  
S proteins form homotrimers (33) and are co-translationally N-glycosylated, after 
which the carbohydrates are processed in the endoplasmic reticulum and in the Golgi 
apparatus (55, 134). The majority of the S protein in virus-infected cells localizes in the 
ER and Golgi intermediate compartment (ERGIC) but when the S protein is expressed 
by itself, it is transported to the plasma membrane. This implies that some other viral 
protein interacts with S protein and localizes to the budding sites. In addition, an excess 
amount of S protein expressed in infected cells is transported to the plasma membrane 
inducing cell-cell fusion of neighboring cells thus promoting virus spreading. 
Newly synthesized proglycoprotein S is cleaved by carboxypeptidase-like 
activity in vivo or by trypsin in vitro into S1, the N-terminal product and S2, the C-
terminal product. The cleavage site lies near the center of the protein at a cluster of basic 
amino acids (37). This cleavage has been shown to be required for the activation of viral 
infectivity and cell fusion in MHV {Sturman, 1985 #136, 181). IBV-Beaudette S1 and 
S2 are comprised of 514 amino acid residues (56.2 kDa), and 625 amino acid residues 
(69.2 kDa), respectively. The amino acid cleavage sites of IBV and MHV S1 and S2 
were identified by partial amino terminal sequencing of spike polypeptide, S2, which 
was identified as RRFRR for IBV and RRAR(H)R for MHV (37, 117).  
However, in the case of FIPV, TGEV and likely SARS, the S protein dose not have a 
cleavage site (78). Major neutralization epitopes, which determine the serotypes of IBV, 
map to the S1 protein (36). This protein interacts with cellular receptors, whereas the S2 
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is responsible for anchoring S1 into the viral envelope and for cell membrane fusion. 
Cellular receptors for several coronaviruses have been identified. Two cellular receptors 
have been identified for MHV. MHVRI and MHVR2, which are translated from the 
same mRNA through alternate splicing and are expressed in different tissues (46) (58).  
Integral membrane glycoprotein (M) is the most abundant envelope glycoprotein of 
coronaviruses (152). It is composed of 225 amino acids in IBV. Its predicted molecular 
weight, based on amino acid sequence data is about 25 kDa. However, the actual 
molecular weight in infected cells is about 30 kDa. M protein expressed in infected cells 
or expressed from cDNA transcripts has several isotypes. The MHV has five different 
isotypes that can be distinguished electrophoretically ranging from M0 to M5 (83, 150, 
191. This molecular weight discrepancy is based on different glycosylation of the M 
protein depending on the location of the protein in different intracellular compartments 
{Locker, 1992 #332)(106). M proteins of coronaviruses also differ in glycosylation and 
localization. MHV has O-linked glycosylation and targets to the trans-Golgi apparatus 
(110, 135, 178) whereas IBV has N linked glycosylation (32, 108) and targets to cis-
Golgi (118).  
The M protein spans the membrane bilayer three times, having a short glycosylated 
amino terminal domain on the exterior of the virus and a large carboxyl terminus, 
containing more than half the mass of the molecule, in the virion interior (5, 111, 151). 
In contrast to other viral glycoproteins, M protein doesn’t have a signal sequence at its N 
terminal but has internal signal sequence in the membrane-spanning hydrophobic 
regions (148). In IBV, the first transmembrane domain appears to be sufficient for 
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retention of the protein in the Golgi (182), whereas the cytoplasmic tail and at least one 
transmembrane domain of the MHV-M protein are necessary for viral retention at the 
trans-Golgi (109).  
The M protein is an important viral structural protein. Its interaction with S protein is 
important for the incorporation of S protein into a virus particle. S protein can be 
expressed on plasma membranes without the presence of M protein expression, however 
if the S protein is co-expressed with M protein, it localizes to the ER-Golgi intermediate 
compartment which is suggested as a virus budding site (118, 149) (189). M and S 
protein interaction in MHV has been shown (137). Transmembrane domains and 
amphipathic domains of the M protein are necessary for interaction with S in MHV (52). 
Targeted mutagenesis of MHV and FIPV has shown that without the proper TM and 
endodomain of the S protein, the ectodomain of different species S protein cannot be 
incorporated into virus particles (53, 66). This study suggested that TM and endodomain 
of the S protein might interact with the M protein. The M protein is also important for 
virus budding and assembly with E protein. The M protein has been shown to have an 
affinity for RNA even though the domain of M that interacts with the RNA or RNP is 
not known (179). Recently, Narayanan et al. (128) suggested that M protein provides the 
specificity of viral genomic RNA packaging by interacting directly with the packaging 
signal sequence of MHV genomic RNA. Monoclonal antibodies specific for the M 
protein do not neutralize virus infectivity, suggesting that M protein is not involved in 
virus attachment to receptors. 
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The third glycoprotein on the virion surface is HE. It is present in BCV, TCV, 
HCoV, and some strains of MHV, but is not present in IBV or TGEV. It is also an N-
linked glycoprotein. This glycoprotein shares some sequence homology with the 
hemagglutinin protein of influenza C virus, and it is proposed that HE protein of these 
coronaviruses is derived from the influenza virus by non-homologous recombination 
(116). HE protein of BCV exhibits hemagglutinin and esterase activity and some strains 
of MHV also show esterase activity. Monoclonal antibodies specific for the HE protein 
of BoCV can inhibit virus-induced hemagglutination and neutralize viral infectivity 
implying that at least in BoCV, HE is involved with S protein for viral attachment. 
The E protein was recently recognized as a structural protein (104, 203). This protein 
in IBV is comprised of 108 amino acids are about 10 kDa molecular weight. In contrast 
to other coronavirus structural proteins, E protein is expressed by cap-independent 
translation from an IRES which is located in the ORF3a and 3b regions or in the 5a 
region in MHV (106, 188). E protein localizes in the perinuclear region with a small 
amount migrating to the cell surface (203). The E protein is anchored in the membrane 
by a sequence in the N-terminal half of the protein and is largely embedded within the 
viral membrane with only a hydrophilic C-terminus protruding inside the virion (121).  
Co-expression of E and M proteins produces virus like particles (VLP) without viral 
RNP. However, expression of the E proteins of MHV or IBV produces vesicles that can 
be released from the cells in the absence of other viral proteins (47, 120). Co-expression 
of M and E are necessary in TGEV and bovine coronavirus (BoCV) to make virus-like 
particles (VLP) (13, 17, 193). E protein has been suggested to “pinch off the neck” of the 
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assembled virus particle from cells during the final stages of budding (193), implying 
that an E protein is essential for VLP formation in every coronavirus. However, Kuo et 
al. (85) has shown that an E deletion mutant of MHV is still viable, although it grow 
poorly and with delayed kinetics. The exact role of E protein in the virus assembly 
process and budding is not yet clear. Direct interaction between the E and M proteins has 
not been demonstrated. It is possible that such an interaction would serve to facilitate the 
budding of virus particles.  
The N protein is the only phosphorylated structural protein in the coronavirus (198). 
N protein is composed of 409 amino acids having a molecular weight of about 50 kDa in 
IBV (22). Coronavirus nucleocapsid sequences vary among major antigenic groups but 
are highly conserved within groups (199). The N protein has basic residues that occur in 
clusters depending on the virus, serine residues account for 8 to 10% of the total amino 
acids in N proteins and the abundance of serine residues count for the specific 
phosphorylation on serine residues in MHV (170). 
N protein is considered a multifunctional protein playing important roles not only as a 
structural protein but also as a protein involved in viral replication and transcription. N 
protein interacts with viral genomic RNA forming a helical nucleocapsid (RNP) and 
interacts with subgenomic RNAs in the cytoplasm. MHV N protein has been shown to 
interact specifically with the 5’ leader containing sequences (10). MHV and IBV-N 
proteins can be divided into three structural domains. The middle domain is an RNA-
binding domain that binds to both coronavirus and non-coronavirus RNA sequences in 
vitro in MHV (125, 130). However, there is no known RNA binding motif in 
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coronavirus N protein. In the case of IBV, C terminal and N terminal regions of N 
protein but not the middle region interact with the 3’ end of the non-coding region of 
IBV genomic RNA (43, 205). Antiserum raised against N protein inhibited the synthesis 
of the genome-sized RNA by 90% in an in vitro replication system implying N protein is 
involved in transcription or/and translation of the viral genome (45). Several reports 
implied that the phosphorylation status of the N protein might be involved in the control 
of viral transcription and replication.  
 
REPLICATION OF CORONAVIRUSES 
Coronaviruses replicate in the cytoplasm of infected cells, preferentially in epithelial 
cells. It has been shown that the MHV can replicate inside the enucleated cell implying 
that the host nucleus and/or nuclear factors are not involved in virus replication. 
However, studies with IBV and a human coronavirus have shown that the replication of 
these viruses is hindered by α-amanitin treatment or in enucleated cells (61). This 
suggests that maybe some host nuclear factor(s) are involved in virus replication, at least 
for IBV and HCoV. Coronavirus replication does not completely shut down the cell 
replication cycle and continuous host translation is necessary for viral replication (154). 
The replication complex of coronaviruses has been described to be associated with late 
endosomal membranes by colocalization of viral replicase and newly synthesized RNA 
with a late endosomal marker by immunofluorescence assay (IFA) and electron 
microscopy (EM) (166, 192). This replication complex translocates to the virus budding 
site, ERGIC, at late times post infection (20). 
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Coronavirus replication also needs continuous viral protein translation and N protein 
(45). Inhibitors of protein synthesis, such as cycloheximide, inhibit RNA synthesis 
(122). Dependency of RNA synthesis on protein synthesis continues throughout the viral 
replication cycle. The RNA polymerase or some cofactors have to be continuously 
synthesized. Negative-stranded and positive-stranded coronavirus RNA synthesis have 
different sensitivities to inhibition by cycloheximide (154), implying that the negative 
and positive-stranded RNAs are likely synthesized by two different polymerase 
activities. Two enzymatically distinct RdRp activities, one acting early and the other 
during late infection, have been described (24) even though there are some 
inconsistencies between studies (45, 122). 
Coronaviruses employ several different strategies to translate their structural or non-
structural proteins in infected cells. First, several subgenomic RNAs are produced that 
are functionally monocistronic, expressing only the extreme 5’ ORF. Second, it exploits 
ribosomal frameshifting and post-translational cleavage of polyproteins. Finally, an 
IRES is used to translate proteins in a cap-independent manner from polycistronic ORFs. 
 
Attachment and Penetration 
Attachment and penetration are complex processes that have not been 
characterized in detail for most coronaviruses. The virion binds to the cell membrane 
receptors by either the S or HE glycoproteins (42). IBV entry into susceptible cells 
occurs at both at 4°C and 37°C (138). Conformational changes in either of the viral 
proteins S or HE may be induced by virus binding to the cellular receptor and lead to 
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fusion of the virus envelope with host cell membranes (46). MHV-A59-induced fusion is 
optimal at neutral or mildly alkaline pH (180). Other coronaviruses, such as HCV-229E, 
IBV or some strains of MHV do not fuse at neutral pH and the fusion occurs in 
endosomal membranes rather than the plasma membrane (64). Coronaviruses generally 
are highly species specific in vivo and in vitro. The species specificity appears to be 
mediated at the site of entry, since MHV genomic RNA is infectious and MHV 
replicates efficiently in nonpermissive hosts that express the MHV receptor. In addition, 
a recombinant FIPV with the MHV S protein can replicate in murine cell lines (71). 
Receptors for the MHV virus have been identified. MHV receptor (MHVR) is a member 
of the carcinoembryonic antigen-cell adhesion molecule (CEACAMs) family of 
glycoproteins (200). Subsequently, MHVR (2d) was found as a splice variant of MHVR 
(4d) (58). Membrane expression of this molecule renders MHV resistant cells, such as 
human and hamster cells, susceptible to MHV infection (58, 59). Aminopetidase N 
(APN), a membrane bound metalloprotease, has been identified as a receptor for TGEV 
and HCV-229E. In humans, hAPN is also known as CD13 (54). TGEV and HCV-229E 
both utilize only species-specific APN glycoproteins as receptors. This indicates that not 
only the attachment to receptors, but also possibly some other host factor(s) are involved 
in host specific virus infection (45). Several studies implicate the involvement of HE 
protein in virus attachment in MHV and even more so in BCV. However, these studies 
need to be expanded. After virion attachment onto its cellular receptor, virus will be 
internalized and targeted to the cellular organelles where the virus will replicate. 
Mechanisms of replication are not yet well studied in coronavirus. 
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Viral Transcription 
Similar to most positive stranded RNA viruses, after the release of the genomic 
viral RNA into host cells, replication begins with the viral RNA serving as the 
messenger for RdRp synthesis. The polymerase transcribes the genomic RNA into a 
negative stranded full length RNA and the negative stranded subgenomic RNA serve as 
templates for the synthesis of subgenomic and genomic RNAs (93). The presence of 
multiple subgenomic mRNAs is a characteristic feature of coronaviruses. Depending on 
the coronavirus, five to eight subgenomic RNAs are transcribed in infected cells. They 
have 5’ and 3’ untranslated regions (UTR) and a poly(A) tail of about 100 nts. The 
extreme of 5’ end of each subgenomic RNA has a stretch of 65-98 nucleotides, referred 
to as the leader sequence. The leader sequence is identical to the sequence at the 5’ end 
of the genomic RNA and is not found elsewhere in the genome (89, 91). However, the 
sequences between each gene, termed the intergenic sequences (IG) or transcription 
regulatory sequence (TRS), have a sequence homology of 7 to 18 nucleotides with the 3’ 
end of the leader sequence (28). The core sequence of the IG sequence for MHV is 
AAUCUAAAC, whereas the 3’ end of the leader consists of several tandem repeats of 
UCUAA (88). The consensus sequence for IBV is CU(U/G)AACAA, AUCUAAAC is 
the consensus sequence for BoCV, and AACUAAAC is the consensus sequence for 
FIPV and TGEV (170). Because of the characteristics of coronavirus transcription that 
produces subgenomic RNAs, and function of leader sequences, several models have 
been proposed to explain the generation of subgenomic RNAs for coronavirus mRNA 
transcription. Two facts exclude splicing as the mechanism to produce subgenomic 
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RNA. First, in ultraviolet (UV) transcriptional mapping studies, the UV target size of 
each mRNA is equivalent to its physical size, indicating that each mRNA is transcribed 
independently, and is not derived from the process of a large precursor RNA (79, 174). 
Second, because coronaviruses replicate solely in the cytoplasm, the possibility of 
splicing as a mechanism for coronavirus transcription mechanism is excluded. 
One coronavirus transcription model is the leader-primed model. This model is 
illustrated in Figure 4. According to this model, discontinuous transcription occurs 
during positive stranded RNA synthesis. Leader RNAs are transcribed at the 3’ end of 
the negative stranded RNA template, before dissociating from the template, and 
subsequently binding to any IG or TRS on the negative stranded template. The leader 
RNA serves as the primer for subgenomic RNA transcription, resulting in a subgenomic 
RNA that contains a leader RNA fused to the mRNA. This model is based on the 
presence of free leaders in infected cells. Several small leader sequence-related RNA 
species have been detected in the cytoplasm of MHV-infected cells (11). These leader 
RNAs are distinct in size and reproducible in different cell types. However, most of 
these leader RNAs are either larger or smaller than the leader sequence present at the 5’ 
end of the mRNAs, implying that additional processing of these leader RNAs may occur 
during mRNA transcription. A temperature-sensitive (ts) mutant has been isolated that 
synthesizes only the small leader-related RNAs, but not mRNAs, at the nonpermissive  
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FIG. 4. The leader-primed model of coronavirus transcription 
5’  
Negative sense RNA 
Genomic RNA 
Anti-TRS TRS Anti-leader Leader 
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3’  UUUUUUUU
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temperature (11). Thus, the possibility that the synthesis of the leader RNA and mRNAs 
are two separate and discontinuous events is supported by in vivo and in vitro studies.  
When different strains of MHV were coinfected into cells or exogenous leader RNA was 
introduced into virus infected cells, heterologous MHV leader sequence was 
incorporated in trans into subgenomic mRNAs at the precise leader-mRNA junction 
sites (7). As mentioned before, seven nucleotides are conserved in the TRS in most 
coronaviruses.  
The second model is the discontinuous extension of negative strand transcription 
(156). This model is illustrated in Figure 5. Discontinuous transcription could potentially 
occur during negative-strand RNA synthesis. During negative strand RNA synthesis 
from the full-length genomic RNA template, RdRp pauses at one of the IG or TRS 
sequences and then jumps to the 3’ end of the leader sequence in the genomic RNA 
template, generating a subgenomic negative strand RNA with an antisense leader 
sequence at its 3’ end. This subgenomic negative strand RNA then serves as a template 
for synthesis of mRNAs. Several studies have shown that both genomic and subgenomic 
sized negative stranded RNAs are present even though positive strand RNA is present at 
a higher amount (12, 155, 157, 162). All the negative strand RNAs were in double-
stranded form and no free negative stranded RNA was detected. 
Coronavirus RNA synthesis takes place on membranous structures associated 
with late endosomes. Colocalization of newly synthesized viral RNA and most of the  
gene 1 products have been shown. N protein involvement in RNA transcription has been 
suggested because antibody against N protein inhibits MHV RNA synthesis in vitro.  
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FIG. 5. Discontinuous extension of negative strands model of transcription 
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Recombination 
 
One of unique features of coronaviruses is the high frequency of RNA 
recombination (123). The high rate of recombination in coronaviruses has been 
demonstrated not only experimentally in mixed infections, but also in infected animals 
and in natural infection (82, 86). A calculation of recombination frequencies suggests 
that the entire genome of MHV will have a recombination frequency of roughly 25% (9). 
The recombination frequency is so high that no selection pressure was needed for the 
isolation of recombinants (82, 123). The possible sites of recombination between 
different MHV strains appear to be distributed over the entire genome, even though a 
recombination hot spot was identified near a hypervariable region in MHV and IBV (8, 
195). The high frequency of coronavirus recombination is probably caused by the 
nonprocessive nature of the coronavirus RNA polymerase. Coronavirus replication of 
the genome, except for the leader sequence, may proceed in a discontinuous and 
nonprocessive manner (11). RNA synthesis pauses at sites of extensive secondary 
structure of the RNA template and the incomplete RNA products dissociate from the 
template because of a nonprocessive nature of the coronavirus RNA polymerase. These 
dissociated RNA products then rebind to the RNA template to continue RNA synthesis 
(96). 
 
Viral Assembly 
The genomic RNA synthesis and encapsidation are coupled in MHV-infected 
cells. Because encapsidation requires N proteins, the accumulation of the N protein 
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could possibly tip the balance of RNA synthesis from transcription towards RNA 
replication. The binding of the N protein to RNA has been shown in vitro for many 
coronaviruses (10, 176). The encapsidation by N proteins is necessary, but not sufficient 
for RNA packaging into mature virions. The N protein binding to viral RNA could be a 
regulatory mechanism of RNA synthesis rather than a virion assembly process. Without 
viral infection, coexpression of the M, E, and S proteins results in the assembly of 
coronavirus-like particles that are released from cells (17, 193). The VLPs produced in 
this manner form a homogeneous population that is morphologically indistinguishable 
from normal virions. Thus, coronavirus virion assembly does not require the 
participation of the nucleocapsid, defining a new mode of virion budding. In addition, 
the reverse genetic approach was used to show that S protein is also dispensable in the 
viral assembly, only the M and E proteins without RNP are required for VLP. It has been 
suggested that in MHV, N protein interacts with viral genomic RNA producing helical 
nucleocapsids and then the M protein and packaging signal sequence of genomic RNA 
interact to confer specificity on packaging of the viral genomic RNA into the virion 
(128). 
S protein and M protein interactions are important for assembly to produce 
infectious virus that can function in the virus and receptor interaction. Assembly of S 
protein into the coronavirus envelope is governed by the M and S protein interaction. S 
protein is expressed on the plasma membranes without M protein, but when it is co-
expressed with M protein, it is localized in the ER-Golgi intermediate compartment, also 
known as cis-Golgi, where the virus obtains its lipid bilayer as it buds (83). The carboxyl-
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terminal domain of the S, that includes the S transmembrane domain and an endodomain 
of 64 residues, is sufficient to interact with the M protein and draw the mature S protein 
into particles (66). 
Coronaviruses are assembled at perinuclear membranes by budding into the ER-
Golgi intermediate compartment. From there, the particles are transported in vesicles 
through the secretory pathway to the plasma membrane domain where they are released 
by exocytosis (190). TGEV enters and is released apically (146). MHV-A59 enters 
apically but is released both apically and basolaterally depending on the cell line (145, 
147). HCoV-22E also infects the apical surface and is released apically (194). It is 
believed that polarity of the viral release from the infected cell can affect tropism and 
spread of the viruses whether it will cause systematic infection or local infection. It is 
interesting that coronaviruses causing local infection, such as gastroenteritis and upper 
respiratory disease, are released apically, but the MHV that causes more systemic 
disease such as hepatitis and encephalitis is released mainly basolaterally.  
 
INFECTIOUS cDNA CLONES OF CORONAVIRUS 
 Because of its large size limitation, and regions toxic to E. coli, until recently there 
was no infectious cDNA clone of a coronavirus. Recently, several groups used different 
approaches to overcome the size limitation of coronaviruses and have cloned the 
approximately 30 kb entire genomes of several coronaviruses. The first breakthrough was 
by Almazan et al. (2), using bacterial artificial chromosomes (BAC) to construct an 
infectious cDNA clone of TGEV. Yount et al. (201) used a novel approach to produce an 
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infectious cDNA clone of TGEV. Instead of cloning the entire TGEV genome into a 
cloning vector, they used in vitro assembly using unique restriction enzyme systems. The 
type II restriction enzymes, such as BsmBI and SapI, recognize non-palindromic 
sequences, and digest the DNA outside of the restriction enzyme recognition sequence 
resulting in 3-4 nucleotide overhangs. These nucleotide overhangs are non-palindromic 
and have unique sequence composition. Each DNA fragment digested with these 
restriction enzymes can be religated with compatible overhangs produced by digestion 
with the same enzyme. Subsequently, Thiel and Casais (31, 185) made infectious cDNA 
clones of human coronavirus, HCoV 229E and IBV respectively using vaccinia virus as a 
cloning vector. The entire coronavirus genomes were cloned into vaccinia virus. The 
recombinant virus will infect cells and produce both coronavirus and vaccinia virus, but 
because of their size difference, recombinant vaccinia virus was filtered out. 
 Each approach used to develop infectious cDNA clones of coronaviruses has 
advantages and disadvantages. In addition to the large size of the genome being an obstacle 
developing infectious clones, regions in the polymerase genes are very unstable in bacterial 
plasmid vectors or BAC systems. These problems have been solved by adding an 
additional intron into the BAC system or by breaking down the coronavirus genome into 
smaller fragments for cloning into separate plasmids. These infectious cDNA clones have 
been used to express heterologous genes, demonstrating their potential as expression 
vectors or gene delivery systems (3, 169, 187). Using characteristics of coronaviruses, 
which produce several subgenomic RNAs to express several different proteins, Thiel et al. 
(187) has developed a multigene RNA vector with HcoV-229E. In this study, they 
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expressed three different proteins, chloramphenicol acetyltransferase (CAT), the firefly 
luciferase (LUC) and the green fluorescent protein (GFP) genes by using independent 
TRSs for each gene (187). This study shows the possibility of coronavirus infectious 
cDNA clones as an alternative for gene delivery systems or expression vectors. 
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CHAPTER II 
 
SYSTEMATIC ASSEMBLY OF A FULL-LENGTH INFECTIOUS cDNA OF A 
BEAUDETTE STRAIN OF INFECTIOUS BRONCHITIS VIRUS (IBV) 
 
INTRODUCTION 
Infectious bronchitis virus (IBV) is one of the most economically important 
diseases in the poultry industry (39). The mortality of the disease varies, depending on 
the viral strain, but the acute and chronic effect of disease such as the retarded growth of 
broilers and a decrease in egg production in layers causes tremendous losses in the 
industry (6).  
IBV belongs to the order of Nidovirales, genus Coronavirinae. The genomes of 
these viruses are 5’ capped, 3’ polyadenylated, and are positive sense RNA (34, 161). As 
with other positive strand RNA viruses, after infecting susceptible cells, the IBV genome 
is used as an mRNA to express its replicase. IBV expresses its proteins using 
subgenomic RNAs (sgRNA) and an internal ribosomal entry site (IRES) (95, 106). IBV 
sgRNAs are structurally polycistronic, but functionally monocistronic with the exception 
of RNA 3 and RNA 5. RNA 3 is a tricistronic mRNA which expresses 3a, 3b, and 3c 
proteins (103). Among these, 3c is a structural protein, the small envelope protein, E 
(104, 203). RNA 5 expresses two proteins, 5a and 5b. Even though expression of these 
proteins in infected cells has been shown (105), the function of these proteins have not 
been addressed. Expression of E protein from RNA 3 uses an IRES, but the mechanism 
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of 3b and 5b expression is speculated as a leaky scanning mechanism but has not yet 
been shown experimentally.  
 IBV can be classified into several different serotypes depending on the S1 
protein of the virus (65). Since some vaccine strains of IBV cannot cross protect against 
IBV strains with distinct serotypes, problems in controlling the disease are continuing to 
arise in field situations. In addition, because of the innate nature of the polymerase gene 
in RNA viruses, the IBV polymerase does not have proof reading ability. In addition, 
frequent recombination between different strains of viruses causes the emergence of 
naturally occurring new types of recombinant viruses in the field causing vaccine breaks 
(86). 
 Molecular biology studies of many viruses, including both positive and negative 
strand viruses, have been accelerated by a reverse genetic systems (23, 62, 141). Infectious 
cDNA clones have been used to address mechanisms of viral replication, pathogenesis, 
virus packaging and in the development of vaccines not only for single stranded genomic 
RNA viruses, but also for segmented viruses, such as Influenza virus (72, 75, 131, 132).  
Infectious cDNA clones of coronaviruses were difficult to generate because of their 
large genome size and the instability of its genes in bacterial plasmids. However, several 
groups have recently developed infectious cDNA clones of coronaviruses (2, 31, 201, 
202). Several approaches were used to overcome the size limitation of the coronavirus 
genome to successfully clone the entire genomes. One of the first breakthroughs was by 
Almazan et al. (2) using bacterial artificial chromosomes (BACs) as a cloning vectors to 
construct an infectious cDNA clone of TGEV. Yount et al. (201) used a unique approach 
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to produce an infectious cDNA clone of TGEV. Instead of cloning the entire TGEV 
genome into cloning vectors, they used in vitro assembly of several cDNAs using a unique 
type II restriction enzyme system that recognize non-palindromic sequences and digested 
the DNA outside of the restriction enzyme recognition sequences. By using enzymes such 
as BglI and BsmBI, each DNA fragment was religated with neighboring fragments that 
had compatible sequence composition. Following this procedure, Thiel and Casais (31, 
185) made infectious cDNA clones of human coronavirus, HcoV 229E and IBV 
respectively, using vaccinia virus as a cloning vector. Yount et al. also developed a new 
strategy to construct an MHV infectious cDNA clone (202). By introducing restriction 
enzyme recognition sequences in MHV genomes by RT-PCR that can be used for in vitro 
assembly without introducing nucleotide sequence changes, Yount et al. used the 
characteristics of the restriction enzyme and coined the term "no see’m technology”. After 
digestion of the amplicons with the restriction enzyme and in vitro ligation, the restriction 
enzyme recognition sequences introduced by PCR disappear. 
We used this in vitro assembly strategy to construct an infectious cDNA clone of 
IBV using restriction enzymes BsmBI and SapI. Our aim was to develop a rapid process to 
make IBV vaccines that can effectively control the outbreak of new IBV strains in the 
field. To develop an effective vaccine against IBV, it is critical to know the biology of the 
virus, especially with regards to the genes of the virus involved in viral attenuation and 
pathogenicity. As mentioned before, to understand the molecular biology of RNA viruses, 
the development of an infectious cDNA clone is very useful. In this study, we developed 
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an infectious cDNA clone of IBV using the cell adapted Beaudette strain which is easily 
manipulated in a short time frame.  
 
MATERIALS AND METHODS 
Viruses and Cells  
A Vero cell adapted Beaudette strain of IBV was obtained from American Type 
Culture Collection (ATCC, Manassas, VA) and then plaque purified three times. The 
virus was propagated in the African green monkey kidney Vero cell line, obtained from 
the ViroMed Laboratory (Minnetonka, MN) and maintained in Dubecco’s modified 
Eagle medium (DMEM) containing 5% fetal bovine serum (FBS) supplemented with 
penicillin G (100 unit/ml) and streptomycin (100 ug/ml). The baby hamster kidney cell 
line, BHK-21, was also obtained from Viromed and maintained in DMEM containing 
10% FBS supplemented with antibiotics as described for the Vero cells. 
 
RNA Preparation 
Viral RNA was prepared from the supernatant of IBV infected Vero cells. 
Briefly, Vero cells were infected with IBV at 0.1 multiplicity of infection (m.o.i) and 
incubated in a CO2 incubator at 37°C until the cells showed more than 80% 
cytopathogenic effect (CPE), such as syncytia formation. The cells showing extensive 
CPE were frozen and thawed three times and then cell debris was pelleted by 
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centrifugation at 3,000 rpm using a tabletop centrifuge (CR 412; Jouan Inc. Winchester, 
VA). The supernatants were then ultracentrifuged at 35,000 rpm for 2 hours at 4°C using 
an L7-55 ultracentrifuge (Beckman, Palo Alto, CA) with an SW55Ti swinging bucket 
rotor to pellet the virus. The viral pellet was re-suspended in small volumes of TEN (10 
mM Tris-Cl, pH 8.0, 1 mM ethylendiaminotetraacetate (EDTA), pH 8.0 and 0.1 M 
NaCl) buffer. 
TRIZOL reagent (Invitrogen, Carlsbad, CA) was used to extract the RNA from 
the re-suspended viral pellet following the manufacturer’s instruction. Briefly, 1 ml of 
TRIZOL reagent was added into 200 ul of viral pellet suspension in TEN buffer and then 
mixed thoroughly by inverting the microfuge tube several times. The mixture was 
incubated for 5 minutes at room temperate and then 200 ul of chloroform was added 
before mixing thoroughly by inversion. The mixture was then incubated at room 
temperature for 3 minutes. To separate the aqueous and the organic phases, the mixture 
was centrifuged at 12,000 rpm for 15 minutes at 4°C using a microcentrifuge (5417 R ; 
Eppendorf, Hamburg, Germany). The upper (aqueous) phase was then transferred to a 
new nuclease free microfuge tube and 0.5 volume of isopropanol was added to 
precipitate the RNA. After 10 minutes incubation at room temperature, the RNA was 
pelleted by centrifugation at 12,000 rpm for 15 minutes at 4°C. Before suspending the 
RNA pellet in nuclease free-water, the RNA pellet was washed with 70% ethanol, and 
briefly air-dried. The RNA solution was quantified using a SmartSpecTM 3000 
spectrophotometer (BIO-RAD, Hercules, CA) and stored at –70°C until further use as a 
template for RT-PCR or as a size marker for electrophoresis. 
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Reverse Transcription (RT) Reaction 
The cloning strategy for a full-length infectious cDNA clone of IBV is illustrated 
in Figure 6. This cloning strategy uses SapI or BsmBI restriction endonuclease to cleave 
at specific sequences (Figure 7) leaving highly variable three or four nucleotide 
overhangs that do not randomly self-ligate, but do ligate with the fragments containing 
the complementary nucleotide overhangs generated with the identical restriction 
enzyme. 
The first cDNA reaction was done using the SUPERSCRIPTTM First-Stranded 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) according to the 
manufacture’s directions. Briefly, 1-2 ug of RNA in 8 ul of nuclease free water with 1 ul 
of 10 mM deoxynucleotide-triphosphate (dNTP) and 10 pmol of each reverse primer 
P1R, P2R, P3R, P4R and GNR (Table 1) were incubated in a 70°C water bath for 5 
minutes. Reactions were chilled on ice for 5 minutes before adding 2 ul of 10X first 
strand buffer, 4 ul of 25 mM MgCl2, 2 ul of 0.1 M dithiothreitol (DTT), 1 ul of 
recombinant RNase inhibitor (50 unit/ul, Invitrogen) and 1 ul of Superscript reverse 
transcriptase (50 Unit/ul) and then incubated at 42°C for 50 minutes. The reaction was 
terminated by incubating at 75°C for 15 minutes before degrading the RNA template 
with 1 ul of E. coli RNase H (2 Units/ul) with 20 minutes incubation at 37°C. 
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FIG. 6. Strategy for orderly assembly of an IBV infectious cDNA clone. Using RT-
PCR and unique oligonucleotide primer mutagenesis, seven clones spanning the 
entire IBV genome were amplified using standard recombinant DNA techniques. 
Between P2-1 and P2-2, P3-1 and P3-2, unique BsmBI restriction sites were inserted 
at the 3’ and 5’ end of each junction. The approximate locations of each RT-PCR 
products is shown. T7 RNA polymerase promoter was inserted in front of the 5’ end 
of P1 by PCR mutagenesis. In the same way, twenty nucleotides poly (A) tail was 
inserted at the 3’ end of P5. 
5a and b
M ORF
ORF1a 
ORF1b
S ORF  N
3 a,b, E 
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BsmBI restriction enzyme recognition sequence 
 
5’...CGTCTC(N)1 ⇓...3’ 
3’...GCAGAG(N)5 ⇑...5’ 
 
 
 
Sequence of P2 between P2-1 and P2-2 junction 
 
GCTAGTGTTAAGAGTGTTGTCGCTAGCTATAAGACCGTGTTATGTAAGGT 
CGATCACAATTCTCACAACAGCGATCGATATTCTGGCACAATACATTCCA 
 
NHE R 
 
5’ GCTAGTGTTAAGAGTGTT GTCGCGAGACG 3’ 
3’ CGATCACAATTCTCACAACAGC GCTCTGC 5’ 
 
NHE f 
 
5’ CGTCTCT 
GTCGCTAGCTATAAGACCGTGTTA 
3’ GCAGAGACAGC 
GATCGATATTCTGGCACAAT 
 
5’ GCTAGTGTTAAGAGTGTT GTCGCTAGCTATAAGACCGTGTTATGT 
3’ CGATCACAATTCTCACAACAGC GATCGATATTCTGGCACAATACA 
 
 
 
FIG. 7. No see’m technology using BsmBI restriction enzyme properties. Cloning and 
assembly strategy of P2-1 and P2-2 is illustrated. BsmBI site was inserted using PCR 
mutagenesis at the 3’ end of P2-1, 5’ end of P2-2. Cleavage with BsmBI restriction 
enzyme will create a novel four nucleotides overhang that specifically anneal with the 
complementary four nucleotides overhang generated by an identical BsmBI. Upon 
religation, BsmBI is deleted from the clone and reforms original sequence connecting 
two pieces intact. 
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TABLE 1. Primer pairs used for cloning of the individual IBV amplicons 
 
 
 
Primer Nucleotide Sequence Genome location 
T7P1F 5’-TAATACGACTCACTATAGGACTTAAGATAGATATTAATATA-3’ 1-22 
P1R 5’-CCTTTCCAGAAGAGCAAATCTCC-3’ 2254-2276 
P1F 5’-GGAGATTTGCTCTTCTGGAAAGG-3 2254-2276 
P2F 5’-GATCTTGCTGCGAAGAGCACTTTTG-3’ 8611-8635 
NHER 5’-CGTCTCGCGACAACACTCTTAACACTAGC-3’ 5731-5753 
NHEF 5’-CGTCTCTGTCGCTAGCTATAAGACCGTGTT-3’ 5748-5771 
P2R 5’-CAAAAGTGCTCTTCGCAGCAAGATC-3’ 8611-8635 
P3F 5’-GTAGTGATTCATTGAGACGTTTTG-3’ 15508-15531 
SACR 5’-CGTCTCGGGATCTACTGCAAATGAACATAG-3’ 11926-11949 
SACF 5’-CGTCTCGATCCCCGCGGACACATATTGTAAATATG-3’ 11944-11971 
P3R 5’-CAAAACGTCTCAATGAATCACTAC-3’ 15508-11949 
P4F 5’-CAGGCTCTTCATCAGGGTGTACTG-3’ 20543-20566 
P4R 5’-CAGTACACCCTGATGAAGAGCCTG-3’ 20543-20566 
GNR 5’-GCTCTAACTCTATACTAGCC-3’ 27593-27613 
GNRT 5’-TTTTTTTTTTTTTTTTTTTGCTCTAACTCTATACTAGCC-3’ 27593-27613 
 
Numbers followed the sequence data obtained from Vero cell adapted Beaudette sequence from 
our laboratory. Bold letter is T7 RNA polymerase promoter seq. Underlined letter is BsmBI 
restriction enzyme recognition sequence. 
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Polymerase Chain Reaction (PCR) for Amplification of Target Sequences 
Two ul of each completed cDNA reaction was used to amplify the target DNA 
by PCR. PCR was done using the Expand Long Template PCR system (Roche, 
Indianapolis, IN) following the manufacturer’s directions using a GeneAmp PCR system 
2400 thermocycler (PerkinElmer, Boston, MA). Sequences of the primer pairs used for 
RT-PCR reaction are listed in Table 1. 
cDNA synthesized with P1R primer was used as a template for P1 PCR 
amplification. A 50 ul reaction included 5 ul of 10X PCR buffer number 3, containing 
22.5 mM MgCl2, 2 ul of 10 mM dNTP, 1 ul of forward primer (T7P1F), 1 ul of reverse 
primer (P1R), 2 ul of a cDNA reaction and 0.75 ul DNA polymerase enzyme mix. 
Distilled waster was used to bring the total volume to 50 ul. Reaction conditions for the 
P1 PCR included an initial denaturation at 94°C for 2 minutes, followed by 30 cycles of 
denaturation at 94°C for 10 seconds, annealing at 55°C for 30 seconds and elongation at 
68°C for 2 minutes. The final step was an elongation step at 68°C for 7 minutes.  
P1F and NHER primers were used for P2-1 amplification. NHEF and P2R primers 
were used for P2-2 amplification. P2F and SACR primers were used for P3-1 
amplification. SACF and P3R primers were used for P3-2 amplification. Because P2-1, 
P2-2, P3-1 and P3-2 have a similar target size of about 3.5 kb, the same reaction 
condition was used for these amplifications. 
The conditions for P2-1, P2-2, P3-1 and P3-2 amplification included an initial 
denaturation at 94°C for 2 minute. First round PCR reaction conditions included 10 
cycles at 94°C for 10 second, 58°C for 30 seconds and 68°C for 2 minutes 20 seconds.  
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Conditions for the second round of amplification were 20 cycles at 94°C for 10 seconds, 
58°C for 30 seconds and 68°C for 2 minute 20 seconds, with a 20 second additional 
elongation time in every cycle. A final incubation of 10 minutes at 68°C was included 
for each reaction. 
P3F and P4R primers were used for P4 amplification. Conditions for P4 were an 
initial denaturation at 94°C for 2 minutes followed by 10 cycles at 94°C for 10 seconds, 
58°C for 30 seconds and 68°C for 4 minutes 20 seconds and the second round 
amplification conditions were 18 cycles at 94°C for 10 seconds, 58°C for 30 seconds and 
68 °C for 4 minutes and 20 seconds, with 20 seconds additional elongation time added 
each cycle. This was followed by 10 minutes incubation at 68°C for final elongation. 
P4F and GNR or P4F and GNRT primers were used for P5 amplification. PCR 
reactions included an initial denaturation at 94°C for 2 minutes. First round amplification 
reactions included 10 cycles at 94°C for 10 seconds, 58°C for 30 seconds and 68°C for 6 
minutes 20 seconds and second round amplification, 18 cycles at 94°C for 10 seconds, 
58°C for 30 seconds and at 68°C for 6 minutes and 20 seconds, with 20 seconds 
additional elongation time in every cycle. A final 10 minute 68°C elongation completed 
the amplification. 
 
Cloning of Amplicons 
Following amplification, 2 ul of each PCR product was electrophoresed in a 
0.7% agarose gel, containing Tris-acetate-EDTA (TAE) buffer and ethidium bromide 
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(EtBr). The electrophoresis results were recorded using a FluoChem TM gel analysis 
system (Alpha Innotech Corporation, San Leandro, CA). Each PCR product with the 
correct size was purified from a 0.7% agarose gel containing 100 ul of crystal violet (2 
mg/ml) per 100 ml of agarose solution by electrophoresis. DNA bands were excised 
from the agarose gel and then purified using a QIAquick Gel Extraction Kit (QIAGEN 
Inc., Valencia, CA) following the manufacture’s directions. The concentration of gel 
purified PCR products were measured with a SmartSpec 3000 spectrophotometer (BIO-
RAD). Each PCR product was ligated into a cloning vector. P1 was ligated into a 
pSTBLUE vector (Novagen, Darmstadt, Germany) by incubating an equal molar ratio of 
vector and insert at 16°C for 2 hours. P2-1 though P3-2 were ligated into a pSMART HC 
vector (Lucigen, Middleton, WI) according to the manufacturer’s instructions. Briefly, 
PCR products were treated with T4 DNA polymerase (Promega, Madison WI) filling in 
any 3’ and 5’ end nucleotide overhangs. After T4 DNA polymerase treatment, PCR 
products were treated with T4 Kinase (Promega) to phosphorylate the 5’ ends. The 
products were further purified by phenol/chloroform extraction followed by ethanol 
precipitation. Equal molar ratios of PCR product and pSMART-HC vector were ligated 
for 2 hours at 16°C and then transformed into chemically competent NovaBlue 
(Novagen, Darmstadt, Germany) cells. P4 and P5 PCR products were directly ligated 
into pCR-XL-TOPO cloning vector (Invitrogen) for 5 minutes at room temperature and 
transformed into chemically competent Oneshot cells (Invitrogen). Transformed bacteria 
were plated on Luria-Bertani (LB) medium agar plates containing kanamycin (5 ug/ml) 
and grown overnight at 37°C. 
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Cloning of a Probe 
To prepare a probe for northern and Southern blot analysis that was specific for 
the 3’ end of IBV, a region containing the entire N ORF through the 3’ UTR of IBV was 
RT-PCR amplified and cloned into a pGEM-3Zf(-) vector (Promega, Madison, WI). 
Briefly, the cDNA was prepared using the GNR primer and Superscript reverse 
transcriptase (Invitrogen) as described above. Two ul of a cDNA reaction was used for 
PCR. Taq polymerase (Promega) was used for PCR amplification following the 
manufacture’s directions. 10 pM each of BNF (5’ ATG GCA AGC GGT AAA GCA GC 
3’) and GNR (5’ GCT CTA ACT CTA TAC TAG CC 3’) oligos were added as the 
forward and reverse primer, respectively. The direction of N ORF cloned into pGEM-
3Zf (-) vectors was determined by restriction enzyme digestion using BamHI (Promega), 
and confirmed by sequencing, using M13 forward and M13 reverse primers (Invitrogen). 
Both reverse and forward directions of ORF N were cloned as pGEBN-1 and pGEBN-2, 
respectively.  
 
Nucleotide Sequencing 
Each amplicon DNA was prepared from transformed E. coli cultures grown 
overnight in LB medium, and DNA templates were prepared using a QIAGEN mini prep 
kit (QIAGEN). PCR products purified with QIAquick PCR purification kit (QIAGEN, 
Santa Clarita, CA) were used for direct PCR product sequencing. Sequencing was 
performed using the ABI prism BigDye Terminator Cycle Sequencing Ready Reaction 
Kit (Applied Biosystems, Foster City, CA). The sequencing reaction included 350-500 
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ng of plasmid DNAs or 300 ng of PCR products mixed with 2 ul of BigDye mixture 
(ABI) and 10 pM of primers (synthesized by Integrated DNA Technologies, Inc, 
Coralville, IA) and the reaction mixtures were adjusted to 6 ul with distilled water. The 
conditions for the sequencing reactions included an initial denaturation at 96°C for 2 
minutes followed by 30 cycles at 96°C for 30 seconds, 52°C for 15 seconds and 60°C for 
4 minutes. 
Three independent clones for each amplicon were isolated with plasmid mini-
preparations as described above and sequenced using a panel of primers located about 
400 nts apart on the IBV genome. Unincorporated nucleotides and primers were 
removed using micro Bio-spin chromatography columns (BIO-RAD, Hercules, CA) and 
the sequencing reaction was completely dried using a Speed-Vac Concentrator (Thermo 
Savant, Holbrook, NY). Completed sequencing reactions were sent to a core facility 
sequencing laboratory at the Department of Biology, Texas A&M University. Sequences 
were read using an ABI automatic sequencer 3100 (ABI). 
 
Analysis of Sequences  
Sequence data were analyzed using SDS Biology Workbench 
(http://workbench.sdsc.edu) (San Diego Supercomputer Center, University of California, 
San Diego, CA). For DNA and amino acid sequence comparisons, the LALIGN program 
was used. For cloning purposes, the TACG program was used to search for restriction 
enzyme digestion profiles. SIXFRAME was used to convert DNA sequences into amino 
acid sequences.  
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Assembly of a Full-length IBV Infectious Construct 
Insert DNAs from each amplicon were digested with the appropriate restriction 
enzymes. P1 was digested with XhoI (Promega, Madison, WI) and then treated with calf 
intestine phosphatase (CIP) (Promega) to inhibit self-ligation. CIP treated DNA was 
phenol:chloroform extracted, ethanol precipitated and then digested with restriction 
enzyme SapI (New England Biolabs Inc., Beverly, MA). P2–1, P2-2 and P3-1 amplicons 
were double digested with restriction enzymes SapI and BsmBI. When the buffer 
conditions were not compatible, after one restriction enzyme digestion, the reactions 
were ethanol precipitated and then the DNA was reconstituted with the appropriate 
buffer and in the appropriate volume for the second enzyme digestion. Except for the 
BsmBI restriction enzyme digestion that needed to be incubated at 55°C, the restriction 
enzymes were incubated at 37°C. P3-2 and P4 replicons were single digested with 
restriction enzyme BsmBI. The P5 amplicon was digested with restriction enzyme 
EcoRI (Promega) then CIP treated and digested with BsmBI. Each DNA insert was run 
on a TAE agarose gel (0.8 to 1%) containing 2.4 ug/ml crystal violet to prevent UV-
induced DNA damage that could impact subsequent manipulations of the DNA 
fragment. Target size inserts were excised from the agarose gel and the DNA inserts 
were extracted using a QIAquick Gel Extraction kit (QIAGEN Inc, Valencia, CA) 
following the manufacturer’s instructions. 
A high concentration of T4 DNA ligase (20 U/ul) was used to assemble 
infectious cDNA of IBV. Ligation reactions were incubated at 16°C overnight before 
inactivating the ligation reaction mixes by incubating at 65°C for 10 minutes. Aliquots 
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of the ligation reactions were electrophoresed on an agarose gel to confirm the ligation 
reaction and size of the ligation products. The correct sizes of larger ligation fragments 
were purified from agarose gel and then ligated step wise with other fragments. The final 
ligation reaction of P1 through P3-1 and P3-2 though P5 were pooled without further 
purification and then ligated overnight. 
 
Northern Blot Analysis 
 
Preparation of a random primed isotope labeled probe. 
 To prepare a random primed probe against the 3’ end of IBV, pGEBN-2 was 
used as a template. The template DNA was digested with PstI restriction enzyme and 
then phenol:chloroform extracted followed by ethanol precipitation to remove 
contaminating RNase. One ug of template was used for an in vitro transcription and 
labeling reaction using T7 RNA polymerase (Promega). Briefly, 4 ul of 5X transcription 
buffer, 2 ul of 100 mM DTT, 1 ul of RNase inhibitor (Promega, 30 unit/ul), 4 ul of rNTP 
mix containing 2.5 mM rCTP, rATP, and rGTP, 1.2 ul of 200 uM rUTP, 5 ul of [α-32P] 
rUTP (Perkin-Elmer), 1.3 ul of T7 RNA polymerase (20 unit/ul) were used in a 20 ul 
reaction. The reaction was incubated at 37°C for one hour and then ethanol precipitated. 
The probe was resuspended in deionized formamide and stored at –20°C. Activity of the 
probe was measured with a liquid scintillation system (Beckman Coulter Inc, Fullerton, 
CA) before using for hybridization reactions.  
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RNA transfer 
To transfer RNA from an agarose gel to a nylon membrane for northern blot 
hybridization, 1 ul of each in vitro transcribed RNA was electrophoresed in a denaturing 
agarose gel containing formaldehyde following standard method (153) with 
modifications. RNA was denatured with sample buffer containing 1/10 v/v 
formaldehyde gel–running buffer (0.2 M 3-(N-norpholino) propanesulfonic acid 
(MOPS) (pH 7.0), 80 mM sodium acetate and 10 mM EDTA (pH 8.0)) with 1/5 v/v of 
formaldehyde, 1/2 v/v of deionized formamide, 2 ug of EtBr, and 1/10 v/v of 
formaldehyde gel-loading buffer (50% glycerol, 0.25% bromophenol blue, 0.25% xylene 
cyanol FF) per RNA sample containing total volume of 15 ul of reaction volume. RNA 
and sample buffer were mixed, denatured at 70°C for 5 minutes and chilled on ice. A 1% 
denaturing agarose gel containing formaldehyde was prepared with a 1/10 volume of 
10X formaldehyde gel running buffer and formaldehyde to give final concentration of 
2.2 M formaldehyde. Each RNA sample was loaded on the agarose gel and run at 90 V 
in 1X formaldehyde gel-running buffer. After every one hour, the buffer from each 
reservoir was mixed and returned to the gel apparatus for further electrophoresis. When 
the xylene cyanol dye front was at the bottom of the gel, electrophoresis was terminated. 
The gel was washed several times with distilled water and then soaked in 0.05 N NaOH 
for 20 minutes and exposed to long wavelength UV light for 60 seconds. The gel was 
then washed with distilled water and soaked for 20 minutes in 10 X sodium chloride 
sodium citrate (SSC) buffer. RNA from the gel was transferred to nylon membrane by 
capillary transfer in 10 X SSC overnight. RNA transfer was confirmed by EtBr staining 
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of the nylon membrane and molecular weight markers were indicated with pencil. The 
membrane was then fixed by UV cross-linking for 30 seconds using GS gene linker UV 
chamber (BIO-RAD).  
 
Hybridization reaction 
The membrane containing transferred RNA was hybridized with a probe against 
the 3’ end of the IBV gene with specific activity of 2 x 107 cpm/ug that was labeled with 
α-32P by random priming. Hybridization reactions were done using an autoblot 
hybridization oven (Bellco Glass Inc., Vineland, NJ). Hybridization conditions included 
incubation at 55°C for 12 hours in hybridization buffer containing 50% deionized 
formaldehyde, 2 X Denhardt’s reagent, 5 X SSC and 0.1% SDS. After hybridization, 
excess probe was removed by washing with 1 X SSC, 0.1% SDS, followed by three 
washes for 20 minutes each at 68°C in 0.2 X SSC and 0.1% SDS. After hybridization, 
the nylon membrane was exposed to an image plate (IP) for 20 minutes to one hour, 
depending on signal intensity. The image was analyzed using a BAS-1800 II 
phosphoimage reader (Fusifilm Electronic Imaging Ltd. Tokyo, Japan) and analyzed 
using the Image Gauge V3.12 and L processor V1.72 program. 
 
In vitro Transcription and Electroporation 
Capped runoff T7 transcripts were synthesized in vitro from in vitro ligated IBV 
cDNA template using an mMESSAGE mMACHINE TM T7 Ultra kit (Ambion, Austin, 
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TX) as described by the manufacturer with some modification. 20 ul of IBV RNA 
transcription reaction mixture was prepared containing 10 ul of 2 X NTP mixture, 3 ul of 
30 mM GTP, 2 ul of 10 X transcription buffer, 2 ul of enzyme mixture and remainder 
was filled with nuclease free water and incubated at 37C° for 2 hours. Template DNA 
was removed by incubating the transcription reaction with 1 ul of DNase I (2 units/ul) 
for 20 minutes at 37 C° 
 To increase the efficiency of virus rescue after transfection, N transcript was also 
prepared and co-transfected with the IBV transcript. pGEMN-1 was used as a template 
for N transcripts. The amplicon was digested with a PstI restriction enzyme (Promega) to 
linearize the template and then phenol:chloroform extracted followed by ethanol 
precipitation to remove any RNase contamination. The DNA was resuspended with 
diethyl pyrocarbonate (DEPC) treated distilled water. 1 ug of the template was used for 
an in vitro transcription reaction using mMESSAGE mMACHINE TM T7 Ultra kit 
(Ambion, Austin, TX.). A poly (A) tail was added to the transcript with E. coli Poly(A) 
polymerase. Transcripts were precipitated with 7.5 M lithium chloride containing 50 
mM EDTA before electroporation and transcripts were used with or without 
precipitation.  
BHK-21 cells were grown to about 70% subconfluence before electroporation. 
BHK-21 cells were treated with trypsin to detach them from flasks. The cells were 
washed twice with ice cold DEPC treated PBS and then resuspended at 2 x 107 cells per 
ml in the cold PBS. One third of the transcription reaction using IBV template and one 
fifth of N transcript were mixed with 400 ul of BHK-21 cell suspension in a 1.5 ml 
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microcentrifuge tube. The cells and RNA mixture were immediately transferred to 2 mm 
gap electrophoration cuvettes (electroporation cuvettes plus model No. 620, BTX, 
Genetronics Inc., San Diego, California) and then elecrophorated at 850 V, 25 mΩ and 
at resistance 720 Ω using an electro-cell manipulator 600 (BTX, Genetronics, Inc. San 
Diego, California) with three consecutive pulses. After electroporation, cells were 
incubated at room temperature for 10 minutes and then the transfectant was diluted 1 to 
20 in complete DMEM containing 10% FBS before resuspending with 1 x 106 Vero cells 
per 100 mm cell culture petridish. 
 
Plaque Staining and Plaque Purification 
Virus was serially diluted 10 fold with DMEM without FBS. Then, 200 ul of 
virus dilution was inoculated per well of six well cell culture plates that had been seeded 
with monolayers of Vero cells. After one hour incubation, residual virus was removed by 
washing the cells twice with PBS before overlaying the cells with 0.8% agarose 
containing 1X DMEM, 1% FBS and antibiotics. The cells were incubated until plaques 
were observed. For plaque staining, the agarose overlay was removed using a spatula, 
the cell monolayers were air dried briefly and overlaid with 2 ml of crystal violet 
staining solution per well. After 10 minutes, excessive crystal violet was removed and 
the cells were washed several times with PBS to remove residual crystal violet. For 
plaque purification, the agarose over plaques was picked with a 1000 lambda 
micropipette and suspended in 1 ml DMEM without FBS. The plaque suspension was 
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incubated at 4°C overnight and then the viral suspensions were inoculated onto Vero cell 
in 6 well plates as described before.  
 
Kinetics of Viral Replication 
 Vero cells were infected with wild type IBV Beaudette strain and IBV Beaudette 
strain derived from an infectious cDNA clone and plaque purified three times. The Vero 
cells were seeded in 35 mm petridishes at a concentration of 106 per dish. The cells were 
infected with three plaques forming units per cell for an hour and then the media were 
replaced with DMEM containing 1% FBS with antibiotics, and 5, 10, 12, 19, and 21 
hours after infection, the cells were harvested and stored at –70°C for subsequent plaque 
assays. 
 
RESULTS 
 
RT-PCR and Cloning of Amplicons 
Fragments covering the entire genome of IBV Beaudette were amplified by RT-
PCR. Each fragment overlapped by about 10 nucleotides. The RT-PCR products were 
cloned into cloning vectors and labeled as P1, P2, P3, P4 and P5 and their sizes are 2.2 
kb, 6.3 kb, 6.8 kb, 5 kb and 7.2 kb, respectively, as shown in Figure 8. Some parts of the 
coronavirus genome have been reported to be toxic to bacterial host cells when they 
were transformed into bacterial host cells. This has also been reported during the process  
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M     1     2     3     4     5 
FIG. 8. RT-PCR amplification of the entire IBV genome. The entire genome of IBV 
was RT-PCR amplified into five pieces. The RT-PCR products were separated in a 
0.8% agarose gel and stained with ethidium bromide. M, represents the 1 kb DNA 
ladder; Lane 1, RT-PCR product from nt 1 to 2269; Lane 2, RT-PCR product from 
nt 2269 to 8635; Lane 3, RT-PCR product from nt 8625 to 15520; Lane 4, RT-PCR 
product from nt 15520 to 20550; Lane 5, RT-PCR product from nt 20550 to 17613.  
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of construction of the infectious cDNA clones of TGEV, MHV and IBV (31, 201, 202). 
In this lab, several efforts were made to clone the large RT-PCR products of P2 and P3 
into the pCR-XL-TOPO TA vector (Invitrogen) but without success. Since regions 
within these sequences of IBV were also reported to be toxic to E. coli (31), P2 and P3 
were each divided into 2 smaller fragments. Because there was no SapI or BsmBI 
restriction enzyme recognition sequence inside these regions of the IBV genome, I 
decided to use the “no see’m technology” developed by Dr. Baric’s laboratory (202) to 
insert the BsmBI restriction enzyme recognition sequences. The NHER, NHEF, SACR, 
and SACF primers were designed to hold a BsmBI restriction enzyme recognition 
sequence at the 5’ or 3’ end of each primer as shown in Table 1. In addition, to further 
overcome the toxicity of the IBV gene products in bacterial hosts after transformation, 
we used pSMARTHC-Kan vector (Lucigen) that was developed to avoid transcription of 
plasmid genes in bacterial hosts. The overall strategy used to develop an infectious 
cDNA clone of IBV is illustrated in Figure 6 and 7. After breaking down the P2 and P3 
each into two fragments, these PCR products were successfully cloned into the 
pSMARTHC-Kan vector. 
Compared to MHV amplicons that are known to be relatively unstable (personal 
communication, J. Leibowitz), IBV amplicons are considerably stable. After two or three 
rounds of 200 ml midi-culture preparations, and subsequent subcloning procedures, no 
mutations were found in P2, 3, and P5 amplicons. At nt 6385, nt 11137 and nt 13387, 
there were mutations that affected the amino acid sequence. At nt 6385, and nt 11137, a 
T to C transition resulted in a tyrosine to histidine substitution. At nt 13387, an A to G 
M     1     2     3      4      5
M      1       2      3      4      5      6     7       8 
 54
transition resulted in a glutamic acid to glutamine substitution. These mutations were 
corrected by replacing the region containing the mutation with the same region in other 
clones having correct sequences. 
At nt 25793 in ORF 5b, there was one nucleotide change from A to G resulting in 
an amino acid sequence change from glutamine to arginine. Since the function of the 5b 
is not known, this mutation was not changed to the wild type sequence and served as a 
marker for the infectious cDNA clone. 
 
Sequencing Analysis 
Each amplicon was sequenced from at least three independent clones to exclude 
inherent enzymatic errors that can occur from RT and PCR reactions. Several differences 
were identified in every amplicon. These aberrations were resolved by direct PCR 
product sequencing. Some of the sequence discrepancies were not corrected if the 
sequence differences did not result in a change in the amino acid sequence. If the 
nucleotide change resulted in amino acid sequence changes, these mutations were 
corrected using other amplicons that had the correct sequence. To replace these changes 
with the correct sequences, inserts from independent clones were swapped using unique 
restriction enzyme with correct amplicons. Some regions of the genome do not encode 
proteins but have important secondary structures. This is especially true for the 3’UTR 
region within P5. When there were sequence differences between independent clones for 
the same region, the sequence was corrected according to the direct RT-PCR 
sequencing. 
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Except for the sequence discrepancies between clones for the same amplicons, there 
were 76 genuine sequence differences from the published sequence data (22, 31). 
Sequence differences between the IBV strain used in this study, which has been 
passaged and adapted in Vero cells and the sequence published in 1987 (22) are 
summarized in Table 2. These changes occurred in the entire genome except for the 
RdRp region which was totally conserved indicating that it is critical for viral survival. 
An interesting observation in our study shows a 5 nts insertion in the intergenic region of 
ORF 4 and ORF 5. At this time, the relevance of the 5 nts insertion in the virus is 
unknown. Thus, the Beaudette strain of IBV in our study is 27613 nts instead of 27608 
nts.  
 
Systemic Assembly of Infectious cDNA by In vitro Ligation Reaction 
To assemble a full-length cDNA of IBV, each amplicon was digested with 
appropriate restriction enzyme and insert DNAs from amplicons were purified by 
electrophoresis and gel purified as described in materials and methods (Figure 9).  
Initially, ligation of all the fragments in a single reaction was attempted because 
each fragment, P1 through P5, has a different sequence overhang at the 3’ and 5’ ends 
after digestion with SapI or BsmBI. Theoretically, each fragment cannot be randomly 
ligated to each other, but only with the neighboring sequences, that share compatible 
ends. Therefore, it was hypothesized that it would be possible to connect each fragment 
into an infectious clone in one ligation reaction. However, with the random ligation and 
in vitro transcription reactions, only a shorter RNA transcript was obtained. To increase  
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TABLE 2. Summary of nucleotide and amino acid differences between IBV Beaudette 
used in this study and published sequence 
 Location Nucleotide change 
Amino acid 
change Gene affected 
1 32 C-T - 5’UTR 
2 222 C-T -  
3 282 G-A -  
4 490 T-C -  
5 841 C-T S-P pp1a 
6 1374 G-A -  
7 1845 T-C -  
8 2000 C-T A-V  
9 2015 A-G C-G  
10 2439 A-T G-E  
11 2651 C-T T-M  
12 3169 A-T -  
13 3210 A-G -  
14 3283 A-G K-E  
15 3322 C-A L-I  
16 3428 C-A A-D  
17 3926 T-C L-S  
18 4481 C-A T-N  
19 4791 A-G -  
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TABLE 2 continued 
 Location Nucleotide change Amino acid change Genes 
20 5456 T-C L-H  
21 5785 C-T L-F  
22 5828 C-T P-L  
23 6231 G-A   
24 7293 A-C   
25 7755 A-G   
26 9372 A-G   
27 10754 T-C V-A  
28 10781 T-C I-T  
29 11780 T-A V-D  
30 12136 A-G S-G  
31 13106 C-T  pp1b 
32 13178 A-C Q-H  
33 13646 A-G   
34 15302 A-G   
35 15594 C-A   
36 16286 C-T   
37 16718 A-G   
38 17546 T-C   
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TABLE 2. Continued 
 Location Nucleotide change 
Amino acid 
change Genes 
39 18195 T-C Y-H  
40 20731 T-A L-I S 
41 20755 C-T L-F  
42 21149 A-C N-T  
43 21357 A-T K-N  
44 21457 A-G   
45 21459 A-T   
46 21628 A-C N-H  
47 21711 G-A   
48 22347 T-C   
49 22433 A-G K-R  
50 22415 A-C N-T  
51 22441 C-G L-V  
52 22492 A-G   
53 22535 T-C F-L  
54 22590 C-T   
55 23402 G-T S-I  
56 23724 T-A   
57 24338 T-C   
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TABLE 2. Continued 
 Location Nucleotide change 
Amino acid 
change Genes 
58 24508 C-T P-S  
59 24661 A-G I-V  
60 24716 C-T T-I  
61 25342 G-T   
62 25426 G-A   
63 25458 T-C   
64 25465 C-T   
65 25793 A-G Q-R  
66 25901 A-G   
67 25904 A-G   
68 25928 T-C   
69 26054 C-T  N 
70 26208 G-T D-Y  
71 26403 G-T A-S  
72 26501 G-T Q-H  
73 27048 T-G Y-D  
74 27051 G-T D-Y  
75 27069 A-G N-D  
76 27466 A-C   
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1.5 kb 
FIG. 9. Preparation of insert DNAs from each amplicon. Each amplicon was 
digested with appropriate restriction enzymes and inserts were separated from the 
vectors using agarose gel electrophoresis and DNA gel purification. M, 1 kb DNA 
ladder; lane 1, P1 insert prepared by XhoI digestion, CIP treated and then digested 
with SapI restriction enzyme to cut the insert out from the vector; lane 2, P2-1 
insert digested with BsmBI and SapI; lane 3, P2-2 insert prepared by digestion with 
BsmBI and SapI restriction enzyme; lane 4, P3-1 prepared by BsmBI and SapI 
digestion; lane 5, P3-2 prepared by BsmBI digestion; lane 6, P4 insert prepared by 
BsmBI digestion; lane 7, P5 large fragment prepared by EcoRI digestion followed 
by BsmBI digestion; lane 8, small fragment of P5. 
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the possibility of ligations resulting in an entire genome of IBV infectious clone, each 
fragment was orderly ligated. P1 and P2-1 were ligated together and P2-2 and P3-1 were 
ligated. P3-2 and P4 were ligated and P5L, and P5S were ligated, and then the ligation 
products were extracted from agarose gels. The P1/P21-1 and P2-2/P3-1 were ligated 
together and P3-2/P4 and P5 were ligated. After verifying the ligation of each fragment 
by electrophoresis, without further purification, the two ligation reactions were pooled 
and ligated overnight at 16°C (Figure 10). To verify that the reaction contained the full-
length IBV cDNA template, Southern blot analysis using the probe against the 3’ UTR 
of IBV was done with the final product (data not shown). Only the orderly ligated about 
30 kb cDNA could be hybridized with a probe against the 3’ end of IBV whereas the 
randomly ligated cDNA template could not.  
 
In vitro Transcription and Transfection of RNAs 
 After confirming that the cDNA template contained the full length IBV genome 
by Southern blot analysis, in vitro transcription reactions were performed using the 
purified template. The ligation template was extracted with phenol:chloroform and then 
ethanol precipitated to remove ligase and contaminating RNase. Approximately 0.2 pm 
of cDNA template was used for one in vitro transcription reaction. To confirm that the in 
vitro transcript had a full length RNA, northern blot analysis was performed using the 
same probe used for southern blot analysis. RNA transcribed from orderly ligated 
template only produce full-length in vitro transcript and could be hybridized with a  
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20, 40 kb 
15 kb 
5 kb 
 
M      1      2      3       4        5        6         7 
FIG 10. Systemic assembly of IBV full–length cDNA. Each amplicon was 
digested with the appropriate enzymes and inserts were purified from agarose gels. 
The inserts were orderly ligated and then larger ligated fragment were purified 
from agarose gels before ligated to neighboring fragments. M represents 1 kb 
DNA extension ladder, Lane 1 ligation reaction P1 with P2-1, lane 2, ligation of 
P2-2 and P3-1, lane 3, P4, purified ligation product P3-2 with P4, lane 4, purified 
ligation product P5, lane 5, ligation products from P1 to P3-1., lane 6, ligation 
products P3-2 through P5, lane 7, final ligation product P1 through P5. 
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probe against 3’UTR of IBV (Figure 11). Because it has been shown that the N 
transcript facilitates coronavirus transcription and increases the efficiency of virus rescue 
after viral RNA transfection (56, 184, 201), we co-transfected IBV N ORF transcripts 
with IBV transcript. Because we created clones of the N protein without a poly(A) tail, 
poly(A) was added using E. coli Poly (A)-polymerase after in vitro transcription. In vitro 
transcripts of IBV cDNA and the N ORF were elecrophorated into BHK 21 cells. Before 
using in vitro transcribed RNA, electroporation conditions were optimized using total 
cellular RNA extracted from IBV infected Vero cells. The transfection efficiency was 
higher when more than 2 ug of RNA and lower voltage was used with consecutive 
pulses rather than high voltage with a single pulse. Because BHK 21 cells are not 
susceptible to IBV infection, Vero cells were overlaid with electroporated BHK 21 cells. 
After 3 days transfection, the cells were overgrown and there was no evidence of CPE 
except apparent ballooning of some Vero cells. Subsequently, the cells were frozen and 
thawed three times and then passaged into new Vero cells. Cytopathogenic effect (CPE) 
was observed in the cells infected with supernatant from the cells transfected with IBV 
viral RNA 2 days after infection. CPE was noticed in the cells infected with supernatant 
from the cells transfected with in vitro transcribed RNA 3 days after infection. Both wild 
type IBV and molecularly cloned IBV showed the same syncytia morphologies. 
 To verify whether the virus was derived from the infectious cDNA clone or was 
just contamination, we did direct PCR product sequencing. The infectious cDNA clone 
has one nucleotide sequence difference from the wild type Beaudette strain in ORF 5b. 
Both the positive control, transfected with viral RNA, and a sample that is transfected  
1         2         3 
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RNA 3 
RNA 2 
RNA 1 
FIG. 11. In vitro transcribed RNA from in vitro assembled cDNA template 
encompassing the entire genome of IBV. (A) In vitro transcribed products and control 
RNA, total cellular RNA from IBV infected Vero cells were electrophoresed on 
denaturing agarose gel. (B) Northern blot of the RNA transferred to nylon membrane 
and then hybridized with a probe against 3’ UTR of IBV. Lane 1 represents 
intracellular RNA from IBV infected Vero cells; lane 2, in vitro transcription reaction 
using orderly assembled in vitro ligation reaction, lane 3, in vitro transcription reaction 
 
A B
1         2         3 1         2         3 
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 with in vitro transcribed cDNA’s total cellular RNAs were extracted and used for RT-
PCR. ORF5a region containing the mutation was RT-PCR amplified then the PCR 
products were used for direct PCR sequencing. As shown in Figure 12, wild type IBV 
and IBV rescued from the infectious cDNA clone showed sequence difference in the 
marker mutation. 
 
Gross Plaque Morphology  
 To examine whether the virus from the infectious cDNA clone has the same 
properties as the wild type virus, we decided to look at plaque morphology. The virus 
derived form the infectious cDNA clone showed a higher titer than the control wild type 
virus prepared in the similar way. The gross morphology of each virus plaque, however, 
is similar (Figure 13). 
 
Kinetics of Viral Replication 
 Vero cells were infected with wild type IBV Beaudette and molecularly cloned 
virus from the wild type IBV to compare its growth kinetics. As shown in Figure 14, 
wild type virus and cloned virus showed similar growth kinetics.  
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FIG. 12. Sequence comparison of (A) molecularly cloned IBV with (B) the wild type 
IBV Beaudette strain. One nucleotide change was made as a marker for the molecular 
clone of IBV in ORF5b changing the codon from CAA to CGA which confer the 
amino acid change from Gln to Arg. This mutation was confirmed by RT-PCR and 
direct PCR product sequencing.  
A 
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FIG. 13. Molecularly cloned virus plaque morphology. Cultures of BHK cells were 
electroporated with IBV full-length transcripts or total cellular RNA extracted from 
IBV infected Vero cells as a control and seeded with Vero cells in 100 mm cell culture 
dishes. Virus progeny was three time plaque purified and virus stocks were prepared 
in Vero cells. (A) plaque morphologies of molecularly cloned IBV, (B) wild type IBV 
virus plaque morphologies.  
A 
B
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FIG. 14. Growth kinetic comparison of wild type IBV and molecularly cloned IBV. 
Wild type IBV and molecularly cloned IBV were infected to Vero cell with 3 PFU per 
cell and the cells were harvested in 4,8,12,16,20 and 24 hours after infection.  
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DISCUSSION 
Toxicity and instability of the viral genes in bacterial plasmids and lack of the 
molecular biological techniques to clone large RNA genes into cloning vectors has been 
an obstacle for the development of the molecular clones of RNA viruses, especially for 
coronaviruses. However, the development of molecular biological techniques, such as 
RT-PCR, and further development of cloning vectors, such as bacterial artificial 
chromosome, have helped to solve these problems. Many properties of RNA viruses 
have been extensively studied using molecular clones of viruses. These studies include 
not only positive strand RNA viruses but also negative stranded RNA viruses and 
segmented RNA viruses (139).  
Infectious cDNA clones of positive strand RNA and negative strand RNA viruses 
are useful tools for studying the functions of viral genes in viral replication and 
pathogenesis (139). Infectious cDNA clones can be especially helpful for the study of 
non-structural protein function in viral replication and assembly. In addition, infectious 
cDNA clones of RNA viruses can be used as vaccines against the virus from which it 
was derived or for a foreign gene(s) of another pathogen to induce humoral or cellular 
immunity against recombinant proteins. Viruses are themselves the most natural gene 
transfer vehicles. 
 Because of their large genomic size as compared to smaller RNA viruses, there 
was no coronavirus infectious cDNA clones. In the last few years, infectious clones of 
coronaviruses such as MHV, TGEV, HCoV and IBV have been generated. IBV 
infectious cDNA clones have been constructed using vaccinia virus as a cloning vector 
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(31). However, the vaccinia system is time consuming because of its selection process 
for the recombinant vaccinia virus containing infectious cDNA clones of coronaviruses. 
It is also cumbersome to produce mutations in coronavirus genes inside of vaccinia 
virus. Casai et al. mentioned that using the in vitro assembly technique with certain 
modifications was not successful in rescuing infectious cDNA clones of IBV in their 
study. However, in our study we showed that construction of an infectious cDNA clone 
of IBV using an in vitro assembly strategy is possible. We hypothesize that these 
differences are a matter of technique. The only technical difference is the use of unique 
restriction enzymes to inhibit self-ligation of each fragment instead of treating DNA 
fragments with phosphatase. Another factor may include protecting DNA from UV 
damage during the cloning process.  
Furthermore, our study found several sequence differences between viruses even 
though a Vero cell adapted Beaudette strain of IBV was used by both ourselves and by 
Casai et al. These sequencing results are summarized in Table 2. Interestingly, our lab 
strain of IBV has five additional nucleotides compared to published sequence data (22) 
and an insertion between IG of E and M ORF that increases the genome size to 27613 
nts without affecting any ORF. Therefore, as long as the virus genome maintains the 
TRS and start codon of the ORFs, certain small nucleotide changes in the viral genome 
can be tolerated. This might indicate one mechanism this large RNA virus has evolved to 
effectively survive notwithstanding its lack of polymerase proofreading ability.  
Boursnell et al. (22) mentioned that IBV polymerase has a higher fidelity as 
compared to vesicular stomatitis virus (VSV) that shows several sequence differences 
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between independent cDNA clones of same region. In our study, we found several 
sequence differences between individual clones for the same regions amplified in the 
same condition at the same time. These sequence differences could occur during reverse 
transcription reactions or during PCR amplification. However, considering the 
polymerase properties of RNA viruses, it cannot be excluded that IBV polymerase 
produces quasi-species of genomic subgenomic RNA conferring viral evolution such as 
seen in retroviral replication. The study of the properties of coronavirus polymerases 
including fidelity and the discontinuous nature of the polymerase is an interesting area of 
investigation. It is possible that such studies could lead to the discovery of the 
mechanisms of evolution and survival when coping with a high rate of recombination 
and a lack of proofreading ability during the replication of a relatively large RNA 
genome.  
In summary, an infectious cDNA clone of Vero cell adapted, attenuated 
Beaudette strain of IBV was constructed using in vitro assembly and no see’m 
technology that was previously used for the construction of TGEV and MHV. Compared 
to MHV for which individual amplicons are not completely stable during passage in the 
bacterial host, IBV amplicons are very stable after several passages and subsequent 
manipulations. The infectious cDNA clone of the Beaudette strain maintained in our 
laboratory is 5 nucleotides longer than the Beaudette strain of IBV originally sequenced. 
The virus rescued from the infectious cDNA clone showed the undistinguishable 
properties as parental wild type virus. As a marker, a single nucleotide change was made 
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in ORF5b region and the mutation was conserved in the virus rescued from the 
infectious cDNA clone.  
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CHAPTER III 
 
EXPRESSION OF HETEROLOGOUS PROTEIN, GREEN FLUORESCENT 
PROTEIN USING INFECTIOUS cDNA CLONE OF INFECTIOUS 
BRONCHITIS VIRUS (IBV) 
 
INTRODUCTION 
 Infectious bronchitis virus (IBV) is a long recognized problem for the poultry 
industry and has been identified as a causative agent of avian infectious bronchitis since 
1937 (158). Problems controlling virus infection and disease include a high rate of 
mutation and high recombination frequencies causing new variants that cannot be 
protected with live vaccines. Therefore, it has been difficult to develop an efficient vaccine 
against IBV. Even though IBV is one of the fist described coronaviruses, there is little 
known about the molecular characteristics of the virus. In the past three years, however, 
there has been enormous advancement in coronavirus research. Among the major 
advancements is the development of several infectious cDNA clones of coronaviruses that 
include IBV, MHV-A59, TGEV and human coronavirus (HCoV) 229E (31, 185, 201, 
202). Three different approaches have been used to produce infectious cDNA clones of 
coronaviruses.  
The first approach uses bacterial artificial chromosomes (BAC) as a cloning vector 
that is used to construct the infectious cDNA clone of TGEV (2). This approach overcomes 
the cloning size limitation and stability of the genes in conventional cloning plasmid 
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vectors. However, the infectious cDNA in BAC is not stable in bacterial culture because 
some parts of viral sequences are known to be toxic to bacteria. To overcome this problem, 
an intron was inserted in the toxic region. Because cDNA transfected to the cells targets 
the nucleus, the intron will be spliced out when processed in the nucleus and then 
translocated into the cytoplasm (67). The cDNA has been used to express foreign proteins 
and green fluorescent protein and shown to induce lactogenic immunity in sows {Sola, 
2003 #103). TGEV cDNA has also been engineered as a replication-competent, 
propagation-deficient virus vector by deleting E protein from the construct.  
The second approach toward the creation of infectious cDNA constructs uses 
vaccinia virus as a cloning vector. By this method, IBV and HCoV infectious cDNA 
clones have been made (31, 185). Using this method, an infectious cDNA clone of IBV 
was constructed using vaccinia virus to show that S protein can confer host tropism by 
switching the S protein with other strains of IBV that have different cell tropism (30).  
The third approach uses an in vitro assembly technique by which the entire genome 
of MHV and TGEV are cloned into plasmid vectors into several fragments and then the 
inserts are prepared by restriction enzyme digestion and ligated in vitro (201) (202). Using 
special characteristics of certain restriction enzymes such as SapI or BsmBI, non-
palindromic sequences are recognized and cleaved outside of the recognition sequences 
leaving 3 to 4 nts overhangs at both 3’ and 5’ ends. These 3’ and 5’ ends can only be 
religated with the compatible sequences. By using the inherent properties of these 
enzymes, it is possible to introduce restriction enzyme recognition sequences in PCR 
products that can be cleaved out when digested.  
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 Coronaviruses have several accessory proteins. Their genomic locations vary 
depending on the virus and most of their functions are not known. These proteins are 
referred to as group specific genes. MHV has four group specific genes including 2a, HE, 
ORF4 product and 5a. Only the function of HE protein has been described and is known as 
a structural gene, but it’s presence is not necessary for viral replication or infection. Other 
group specific genes of MHV, except HE, also have been shown not to be necessary for 
viral replication in vitro, but they may function in the natural host. When these accessory 
proteins are deleted from MHV, the pathogenicity is significantly decreased. Therefore, 
these genes are good candidate genes for viral attenuation (51). IBV also has several group 
specific genes including 3a, 3b, 5a and 5b. Nucleotide sequence analysis has shown that 5a 
and 5b have the potential to encode two polypeptides of 7.4 and 9.5 kDa, respectively (21). 
Expression of these proteins has been shown in virus infected cells (105). Expression of 5a 
and 5b proteins has been detected throughout the cell with some apparent concentration at 
the perinuclear location (105). It has been reported that a natural IBV mutant with a 
premature termination codon in 3b expresses a truncated form of the viral protein that is 
not necessary for viral replication (163). These data suggest that IBV accessory proteins 
may also not be necessary for viral survival, at least in vitro. 
 In chapter II, I described a successful construction of an infectious cDNA clone of 
IBV-Beaudette, exploiting in vitro assembly and “no see’m technology”. In this study, I 
wanted to answer the question whether IBV accessory proteins are necessary for viral 
replication in vitro using the infectious cDNA clone. For the following study, we sought to 
manipulate the cDNA clone of IBV for use as a gene transfer vector for the expression of 
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foreign protein in virus infected cells. In this study, we hypothesized that IBV 5a protein is 
not important for IBV survival in vitro. To resolve this issue, ORF5a ORF was replaced 
with enhanced green fluorescent protein (EGFP) ORF.  
 
MATERIALS AND METHODS 
Viruses and Cells  
A Vero cell culture adapted Beaudette strain of IBV was obtained from 
American Type Culture Collection (ATCC, Manassas, VA) and then plaque purified 
three times in the laboratory before use. The virus was propagated in the African green 
monkey kidney, Vero cell line obtained from ViroMed Laboratory (Minnetonka, MN) 
and maintained in Dubecco’s modified Eagle medium (DMEM) containing 5% fetal 
bovine serum (FBS) supplemented with penicillin G (100 unit/ml) and streptomycin 
(100 ug/ml). The baby hamster kidney cell line, BHK-21, was also obtained from 
Viromed and maintained in D-MEM containing 10% FBS supplemented with antibiotics 
as described for the Vero cells above. 
 
PCR Amplification and Cloning 
 The overall cloning strategy is illustrated in Figure 15. Three regions were PCR 
amplified to replace ORF5a with enhanced green fluorescence protein ORF (EGFP). 
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FIG. 15. Schematic of cloning strategy used to replace enhanced green fluorescent 
protein with ORF5a. From ORF 4 to the start codon of ORF5a, EGFP ORF, 3’ end of 
ORF5a including a stop codon though 3’ end of IBV genome will be cloned to 
produce three independent amplicons. These amplicons’ inserts were cut out with 
BsmBI restriction enzyme and in vitro ligated to assemble an amplicon that has gene 
from ORF4 to 3’ end of IBV. This was further subcloned using BamHI restriction 
enzyme to produce BPG5 amplicon that has all the structural genes of IBV except 
ORF5a that is replaced with ORF EGFP. 
ORF 1a 
ORF 1b
 
S ORF 
N
5a ORF
5b ORF
GFP ORF
N ORF
M ORF
GFP ORF
5b ORF 
N 
M ORF 
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 ORF M and the intergenic region of ORF M and 5a including the start codon of ORF 
5a, and the 3’ end of ORF 5a including stop codon through end of 3’ UTR of IBV were 
PCR amplified using primer pairs listed on Table 3. EGFP was PCR amplified from 
pLEGFP-N1 vector (Clontech, Palo Alto, CA) as a template using a primer pair that has 
been designed to have BsmBI restriction enzyme recognition sequence at the each 3’ and 
5’ ends. To replace EGFP with IBV 5a ORF, no see’m technology was employed (202). 
Neighboring genes of the 5a ORF have been engineered to be compatible with EGFP 
ORF using a BsmBI restriction enzyme as illustrated in Figure 16. For PCR 
amplification upstream and downstream of ORF5a, the P5 amplicon described in chapter 
II was used as a template.  
 For PCR amplification, the Expand High Fidelity PCR system (Roche, 
Indianapolis, IN) was used throughout the study and primer pairs used for PCR cloning 
though this study were listed in Table 3. For EGFP PCR amplification, 50 ng of 
pLEGFP-N1 vector (Clontech laboratories Inc., Palo Alto, CA), 10 pM of each forward 
and reverse primer (GFPSF and GFPER respectively), 1 ul of 10 mM deoxynucleotide 
triphosphate (dNTP), 5 ul of 10X PCR buffer number 3 (Roche), 8 ul of 25 mM MgCl2, 
and 0.75 ul of thermostable DNA polymerase mixture were added into 200 ul PCR tubes 
and distilled water was added to bring the total reaction volume to 50 ul. Reaction 
condition for the EGFP PCR amplification includes an initial denaturation at 94°C for 2 
minutes followed by 30 cycles of denaturation at 94°C for 10 seconds, annealing at 55°C 
for 30 seconds and elongation at 72°C for 30 seconds. The final step was an elongation 
at 72°C for 7 minutes.  
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      TABLE 3. Sequences of primer pairs used for construction of IBVG 
 
 
 
Primer Nucleotide Sequence 
Location 
 in IBV 
genome 
GFPSF 5’ CGTCTCATGGTGAGCAAGGGCGAGGAG 3’  
GFPER 5’ CGTCTCCGCTTACTTGTACAGCTCGTCC 3’  
5ASR 5’ CGTCTCCACCATCGTCCGTATTTGTTAAGT 3’ 25574-25592 
5AEF 5’ CGTCTCTAAGCGTATACGCCCACCCA 3’ 25658-25678 
BMF 5’ ATGGCGGAAAATTGCACACTTGATTC 3’ 24509-24535 
GNRT 5’ TTTTTTTTTTTTTTTTTTTGCTCTAACTCTATACTAGCC 3’ 27593-27613 
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5a ORF and its neighboring sequence 
 
CAAAAACTTAACAAATACGGACGATGAAA                
GCGTATACGCCCACCCAATC 
GTTTTTGAATTGTTTATGCCTGCTACTTT                
CGCATATGCGGGTGGGTTAG 
 
GFP sequences including start and stop codon 
 
ACCATGGTGAGCAAGGGCGAGGAGCTG  CTCGGCATGGACGAGCTGTACAAGTAAAGC 
TGGTACCACTCGTTCCCGCTCCTCGAC  GAGCCGTACCTGCTCGACATGTTCATTTCG 
 
5ASR 
5’ CAAAAACTTAACAAATACGGACGATGGTGGAGACG 3’ 
3’ GTTTTTGAATTGTTTATGCCTGCTACCACCTCTGC 5’ 
 
GFPSF 
5’ CGTCTCATGGTGAGCAAGGGCGAGGAGCTGTTCAC 3’ 
3’ GCAGAGTACCACTCGTTCCCGCTCCTCGACAAGTG 5’ 
 
 
5a S and GFP S junction after ligation 
 
CAAAAACTTAACAAATACGGACGA TGGTGAGCAAGGGCGAGGAGCTGTTCAC 
GTTTTTGAATTGTTTATGCCTGCTACCA CTCGTTCCCGCTCCTCGACAAGTG 
 
 
 
GFPE R 
5’ CTCGGCATGGACGAGCTGTACAAGTAAGCGGAGACG 3’ 
3’ GAGCCGTACCTGCTCGACATGTTCATTCGCCTCTGC 5’ 
 
5a E F 
5’ CGTCTCTAAGCGTATACGCCCACCCAATC 3’ 
3’ GCAGAGATTCGCATATGCGGGTGGGTTAG 5’ 
 
 
GFP stop codon and ORF5a 3’ end junction sequence after ligation 
 
CTCGGCATGGACGAGCTGTACAAGT AAGCGTATACGCCCACCCAATC 
GAGCCGTACCTGCTCGACATGTTCATTCG CATATGCGGGTGGGTTAG 
FIG. 16. “No see’m technology” used to replace EGFP with ORF5a. Pink nucleotides 
denote BsmBI restriction enzyme sequence inserted primer pairs. Red nucleotides denote 
start codon or stop codon of EGFP and ORF5a. Underlined sequences are the primer used 
to amplified each gene by PCR. 
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The 5ASR and BMF were used as reverse and forward primers, respectively, for 
amplification upstream of ORF5a and ORF M.  50 ng of the template, amplicon P5, 10 
pM of each forward and reverse primer, 1 ul of 10 mM of each deoxynucleotide 
triphosphate (dNTP), 5 ul of 10X PCR buffer number 3 (Roche), 8 ul of 25 mM MgCl2, 
and 0.75 ul of thermostable DNA polymerase mixture were placed in 200 ul PCR tubes 
and distilled water was added to bring the total reaction volume to 50 ul. Reaction 
conditions for the PCR amplification includes an initial denaturation at 94°C for 2 
minutes followed by 30 cycles of denaturation at 94°C for 10 seconds, annealing at 55°C 
for 60 seconds and elongation at 68°C for one minute. The final step was an elongation 
at 68°C for 7 minutes.  
 The 5AEF and GNRT were used as forward and reverse primers respectively for 
amplification downstream of ORF5a to the 3’ UTR of IBV. 50 ng of template, amplicon 
P5, 10 pM of each forward and reverse primer, 1 ul of 10 mM deoxynucleotide 
triphosphate (dNTP), 5 ul of 10X PCR buffer number 3 (Roche), 8 ul of 25 mM MgCl2, 
and 0.75 ul of thermostable DNA polymerase mixture were added into 200 ul PCR tubes 
and the total reaction volume was brought to 50 ul with distilled water. Reaction 
conditions for the PCR amplification includes an initial denaturation at 94°C for 2 
minutes followed by 30 cycles of denaturation at 94°C for 10 seconds, annealing at 55°C 
for 30 seconds and elongation at 68°C for one minute 20 seconds. The final step was an 
elongation at 68°C for 7 minutes.  
 Following amplification, 2 ul of each PCR product was run on a 1% agarose gel 
in Tris-acetate-EDTA (TAE) buffer containing ethidium bromide (EtBr) and the results 
 82
were recorded using a FluoChem TM gel analysis system (Alpha Innotech, Corporation, 
San Leandro, CA). Each PCR product was purified from a 1% agarose gel containing 
crystal violet (2 ug/ ml). DNA bands were excised from the agarose gel and then purified 
using a QIAquick Gel Extraction Kit (QIAGEN Inc., Valencia, CA) following the 
manufacture’s directions. The concentration of gel purified PCR products were 
measured with a SmartSpec 3000 spectrophotometer (BIO-RAD, Hercules, CA). Each 
PCR product was ligated into a cloning vector. EGFP and upstream of ORF5a were 
ligated into a pSTBlue-1 (Novagen, Darmstadt, Germany) according to manufacturer’s 
directions. Briefly, equal-molar ratios of PCR product and pSTBlue vector were ligated 
for 2 hours at 16°C and then transformed into chemically competent NovaBlue cells 
(Novagen, Darmstadt, Germany). Final constructs of the EGFP ORF and the upstream 
region of ORF5a were named as pSTBGFP and pSTBM, respectively. The region 
beginning from downstream of ORF5a to 3’UTR of IBV was ligated into the pCR-XL-
TOPO cloning vector (Invitrogen, Carlsbad, CA) for 5 minutes at room temperature and 
transformed into chemically competent Oneshot competent cells (Invitrogen). The final 
construct was named pCRB3’. Transformed bacteria were plated on Luria-Bertani (LB) 
medium agar plates containing kanamycin (5 ug/ml) and grown overnight at 37°C. Mini-
prep cultures were prepared from the transformed colonies to confirm the insert size and 
direction using unique restriction enzyme recognition sequence in the inserts. The 
construct was confirmed with nucleotide sequencing using the universal primers SP6 and 
T7 primers synthesized in a commercial laboratory. 
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 To assemble recombinant P5G amplicon, pSTBGFP, pSTBM and pCRB3’ were 
digested with BsmBI. Appropriate inserts from each amplicon were gel purified as 
described above. Because pCRB3’ has an internal BsmBI restriction recognition 
sequence other then BsmBI sites at 3’ and 5’ ends inserted by PCR mutagenesis, two 
DNA bands were prepared from pCRB3’ BsmBI digestion reactions. Also, pCRB3’ was 
used as a cloning vector after the restriction enzyme digestion because it has a pCR-XL-
TOPO backbone. Equal-molar amounts of each insert were overnight ligated using T4 
DNA ligase (3 units/ul, Promega) at 16°C and transformed into chemically competent 
one shot competent cells (Invitrogen) by heat shock at 45°C for 30 seconds. Subcloned 
recombinant P5G were confirmed by restriction enzyme digestion and sequencing. 
 
Nucleotide Sequencing 
Each amplicon DNA was prepared from transformed bacterial midi-cultures 
grown overnight and DNA templates were prepared using QIAGEN mini prep kit 
(QIAGEN). Sequencing was performed using the ABI prism BigDye Terminator Cycle 
Sequencing Ready Reaction Kit (Applied Biosystems Inv., Foster City, CA). For a 
standard sequencing reaction, 350-500 ng of plasmid DNA was mixed with 2 ul of 
BigDye mixture (ABI) and 10 pM of primers. The remainder of the reaction mixture was 
adjusted to 6 ul with distilled water. Sequencing reactions were performed using a 
GeneAmp thermocycler (PerkinElmer, Boston, MA) using conditions that included pre-
denaturation at 96°C for 2 minutes and 30 cycles of 96°C for 30 seconds, 52°C for 15 
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seconds and 60°C for 4 minutes. Non-incorporated nucleotides were removed using 
micro Bio-spin chromatography columns (BIO-RAD, Hercules, CA) and completely 
dried using a vacuum drier. Completed sequencing reactions were sent to the Gene 
Technology Laboratory in the Department of Biology in Texas A&M University. 
Sequences were read using an ABI automatic sequencer 3100 (ABI). 
 
Analysis of Sequence  
Sequence data were analyzed using SDS biology workbench 
(http://workbench.sdsc.edu) (San Diego Supercomputer Center, University of California, 
San Diego, CA). LALIGN program was used for DNA and amino acid sequence 
comparison. The TACG program was used to search for restriction enzyme digestion 
profiles for cloning purposes. The SIXFRAME program was used to convert DNA 
sequence into amino acid sequence.  
 
Assembly of a Full-length IBV Infectious Construct 
Inserted DNAs from each amplicon were excised with the appropriate restriction 
enzymes. PI was digested with XhoI (Promega, Madison, WI) and then treated with calf 
intestine phosphatase (CIP) (Promega) to inhibit self-ligation. CIP treated DNA was 
phenol:chloroform extracted, ethanol precipitated and then digested with restriction 
enzyme SapI (New England Biolabs Inc., Beverly, MA). P2–1, P2-2 and P3-1 amplicons 
were double digested with restriction enzymes SapI and BsmBI. When the buffer 
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conditions were not compatible, after one restriction enzyme digestion, the reactions 
were ethanol precipitated and then the reaction was reconstituted with the appropriate 
buffer and in the appropriate volume before adding the second restriction enzyme. 
Except for the BsmBI restriction enzyme digestion that needed to be incubated at 55°C, 
the restriction enzymes were incubated at 37°C. P3-2 and P4 amplicons were single 
digested with restriction enzyme BsmBI. The P5 amplicon was digested with restriction 
enzyme EcoRI (Promega), then CIP treated and digested with BsmBI. Each DNA insert 
was run on a TAE agarose gel (0.8 to 1%) containing 2.4 ug/ml crystal violet rather than 
ethidium bromide to avoid UV-induced DNA damage that could impact subsequent 
manipulations of DNA fragments. Target size inserts were excised from the agarose gel 
and the DNA inserts were extracted using a QIAquick Gel Extraction kit (QIAGEN Inc, 
Valencia, CA) following the manufacturer’s instruction. 
A relatively high concentration of T4 DNA ligase (20 U/ul, Promega) was used 
to assemble infectious cDNA of IBV. Ligation reactions were incubated at 16°C 
overnight, before inactivating by incubating at 65°C for 10 minutes. An aliquot of the 
ligation reactions were run on an agarose gel to confirm the ligation. The appropriately 
sized larger ligation fragments were agarose gel purified and then ligated step-wise with 
other fragments. The final ligation reaction of P1 through P3-1 and P3-2 though P5 were 
pooled without further purification and then ligated overnight at 16°C. 
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RNA Preparation 
Viral RNA was prepared from the supernatant of IBV infected Vero cells or 
recombinant IBVG rescued from transfection. Briefly, Vero cells were infected with 0.1 
multiplication of infection (m.o.i) and incubated in a CO2 incubator at 37°C until the 
cells showed more than 80% cytopathogenic effect (CPE) such as syncytia formation. 
The cells showing extensive CPE were frozen and thawed three times and then cell 
debris were precipitated by centrifugation at 3,000 rpm using a table top centrifuge (CR 
412; Jouan Inc. Winchester, VA). The supernatants were then ultracentrifuged at 35,000 
rpm for 2 hours at 4°C using an L7-55 ultracentrifuge (Beckman, Palo alto, CA) with an 
SW55Ti swing bucket rotor to pellet the virus. The viral pellet was re-suspended in 
small volumes of TEN (10 mM Tris-Cl, pH 8.0, 1 mM ethylendiaminotetraacetate 
(EDTA), pH 8.0 and 0.1 M NaCl) buffer. 
TRIZOL reagent (Invitrogen, Carlsbad, CA) was used to extract the RNA from 
the re-suspended viral pellet following the manufacturer’s instruction. Briefly, 1000 ul of 
TRIZOL reagent were added to 200 ul of viral pellet suspension in TEN buffer before 
mixing thoroughly by inverting the microfuge tube several times. The mixture was 
incubated for 5 minutes at room temperate, 200 ul of chloroform were added and then 
mixed thoroughly by inversion. This mixture was incubated at room temperature for 3 
minutes. To separate the aqueous and the organic phases, the mixture was centrifuged at 
12,000 rpm for 15 minutes at 4°C using a microcentrifuge (5417 R; Eppendorf, 
Hamburg, Germany). The upper phase was then transferred to a new nuclease free 
microfuge tube and a 0.5 volume of isopropanol was added to precipitate the RNA. After 
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a 10 minute incubation at room temperature, the RNA was pelleted by centrifugation at 
12,000 rpm for 15 minutes at 4°C. Before suspending the RNA pellet with nuclease-free 
water, the RNA pellet was washed with 70% ethanol, then briefly air-dried. The RNA 
solution was quantified using a SmartSpecTM 3000 spectrophotometer (BIO-RAD, 
Hercules, CA) and stored at –70°C until it was used for Northern blot analysis or RT-
PCR. 
 
Northern Blot Analysis 
Preparation of a random primed isotope labeled probe. 
 To prepare a random primed probe against GFP and the 3’ UTR, pGEGFP and 
pGEBN-2 were used as templates for in vitro transcription reactions. The template DNA 
was digested with PstI restriction enzyme and then phenol:chloroform extracted 
followed by ethanol precipitation to remove contaminating RNase. One ug of template 
was used for an in vitro transcription and labeling reaction using T7 RNA polymerase 
(Promega). Briefly, 4 ul of 5X transcription buffer, 2 ul of 100 mM DTT, 1 ul of RNase 
inhibitor (Promega, 30 units/ul), 4 ul of rNTP mix containing 2.5 mM rCTP, rATP, and 
rGTP, 1.2 ul of 200 uM rUTP, 5 ul of [α32P] rUTP (Perkin-Elmer), 1.3 ul of T7 RNA 
polymerase (20 units/ul) were used in a 20 ul reaction. The reaction was incubated at 
37°C for one hour and then ethanol precipitated. The probe was resuspended in 
deionized formamide and stored at –20°C. Radioisotope activity was measured with a 
liquid scintillation system (Beckman Coulter Inc., Fullerton, CA).  
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RNA transfer 
To transfer RNA to nylon membranes, 1 ul of each in vitro transcribed RNA was 
run on a denaturing agarose gel containing formaldehyde following the standard 
methods (153) with modifications. RNA was denatured with sample buffer containing 
1/10 v/v of 10X formaldehyde gel–running buffer (0.2M 3-(N-norpholino) 
propanesulfonic acid (MOPS) (pH 7.0), 80 mM sodium acetate and 10 mM EDTA (pH 
8.0)) with formaldehyde, 1/2 v/v of formamide, 2 ug of ethidium bromide, and 1/10 v/v 
of formaldehyde gel-loading buffer (50% glycerol, 0.25% bromophenol blue, 0.25% 
xylene cyanol FF). RNA and sample buffer were mixed, denatured at 70°C for 5 minutes 
and chilled on ice. A 1% denaturing agarose gel containing formaldehyde was prepared 
with a 1/10 volume of 10 X formaldehyde gel running buffer and formaldehyde to give a 
2.2 M final concentration. Each RNA sample was loaded on the agarose gel and run at 
90 V in 1 X formaldehyde gel-running buffer. At one hour intervals, the buffer from 
each reservoir was collected, mixed and returned for electrophoresis. When the xylene 
cyanol dye front was at the bottom of the gel, electrophoresis was terminated. The gel 
was washed several times with distilled water and then soaked in 0.05 N NaOH for 20 
minutes and exposed to long wavelength UV light for 60 seconds. The gel was then 
washed with distilled water and soaked for 20 minutes in 10 X sodium chloride sodium 
citrate (SSC) buffer. RNA from the gel was transferred overnight to a nylon membrane 
by capillary transfer in 10 X SSC. RNA transfer was confirmed by ethidium bromide 
staining of the nylon membrane and the molecular weight markers were indicated with 
pencil. The membrane was then fixed by UV cross-linking for 30 seconds.  
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Hybridization reaction 
The nylon membrane was hybridized to random primed α-32P labeled probes 
with an activity of 2 x 107 cpm. Hybridization reactions were performed using an 
autoblot hybridization oven (Bellco Glass Inc., Vineland, NJ). Hybridization conditions 
included incubation at 55°C for 12 hours in hybridization buffer containing 50% 
deionized formaldehyde, 2 X Denhardt’s reagent, 5 X SSC and 0.1% SDS. After 
hybridization, excess probe was removed with 1 X SSC, 0.1% SDS, followed by three 
washes for 20 minutes each at 68°C in 0.2 X SSC and 0.1% SDS. After hybridization, 
the nylon paper was exposed to an image plate (IP) for 20 minutes to one hour, 
depending on the signal intensity. The image was analyzed using a BAS-1800 II 
phosphoimage reader (Fusifilm Electronic Imaging Ltd. Tokyo, Japan) and analyzed 
using the Image gauge V3.12 and L processor V1.72 programs. 
 
In vitro Transcription and Electroporation 
Capped runoff T7 transcripts were synthesized in vitro from in vitro ligated IBV 
cDNA using an mMessage mMachine kit (Ambion, Austin, TX.) as described by the 
manufacturer with some modifications. Twenty ul of the IBV RNA transcription 
reaction mixture was prepared with three ul of 30 mM GTP stock and incubated at 37C° 
for 2 hrs.  
 To increase the efficiency of virus production, N transcript was also prepared for 
co-transfecting with the entire IBV transcript. pGEMN-1 was used as a template for N 
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transcripts. The plasmid was digested with a PstI restriction enzyme (Promega) to 
linearize the template and then phenol:chloroform extracted followed by ethanol 
precipitation to remove any RNase contamination. The DNA was resuspended with 
diethyl pyrocarbonate (DEPC) treated distilled water. One ug of the template was used 
for an in vitro transcription reaction using mMESSAGE mMACHINE TM T7 Ultra kit 
(Ambion, Austin, TX.). A poly(A) tail was added to the transcript with E. coli Poly(A) 
polymerase. Both transcripts were used, with or without precipitation with 7.5 M lithium 
chloride containing 50 mM EDTA. 
BHK-21 cells were grown to subconfluence (about 70%) before electroporation. 
BHK-21 cells were treated with trypsin to detach them from flasks. The cells were 
washed twice with ice cold DEPC treated PBS and then resuspended in the cold PBS 
with 2 x 107 per ml infectious cDNA transcription reaction. N transcript was mixed with 
the cells in a 1.5 ml microcentrifuge tube. The cells and RNA mixture were transferred 
immediately to 2 mm gap electroporation cuvettes (electroporation cuvettes plus model 
No. 620, BTX, Genetronics, Inc. San Diego, California) and then electroporated at 850 
V, 25 mΩ at resistance 720 Ω using an electro-cell manipulator 600 (BTX, Genetronics, 
Inc. San Diego, California) with three consecutive pulses. After electroporation, cells 
were incubated at RT for 10 minutes and the transfectant was diluted 1 to 20 in complete 
DMEM containing 10% FBS and resuspended with 1 x 106 Vero cell per 100 mm petri-
dish. 
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Plaque Staining and Plaque Purification 
Virus preparations were serially diluted 10-fold in DMEM lacking FBS. Then, 
200 ul of each dilution was inoculated per well of six well cell culture plates that had 
been seeded with monolayers of Vero cells. After a one hour incubation, residual virus 
was removed by washing the cells twice with PBS before overlaying the cells with 0.8% 
agarose containing 1 X DMEM, 1% FBS and antibiotics. The cells were incubated until 
plaques were observed. For plaque staining, the agarose overlay was removed using a 
spatula, the cell monolayers were air dried briefly and overlaid with 2 ml of crystal 
violet staining solution per well. After 10 minutes, excessive crystal violet was removed 
and the cells were washed several times with PBS to remove residual crystal violet. For 
plaque purification, the agarose over the plaques were picked with a 1000 λ micropipette 
and suspended in 1 ml DMEM without FBS. Before inoculating, the plaque suspension, 
the viral suspension was incubated at 4°C overnight and inoculated to Vero cell in 6 well 
plates described before.  
 
Kinetics of Viral Replication 
 Vero cells were infected with wild type IBV Beaudette strain and the IBV 
Beaudette strain derived from an infectious cDNA clone and plaque purified three times. 
The Vero cells were seeded in 35 mm petri dishes at a concentration of 106 per dish. The 
cells were infected with three plaque forming units per cell for an hour and then the 
media were replaced with DMEM containing 1% FBS with antibiotics, and 5, 10, 12, 19, 
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and 21 hours after infection, the cells were harvested and stored at –70°C for subsequent 
plaque assays. 
 
RESULTS 
 
PCR Cloning and Mutagenesis 
 To replace ORF5a with EGFP from the start codon of ORF5a, no see’m 
technology was used because there was no unique restriction enzyme recognition 
sequence at the start codon and the overall cloning strategy is illustrated in Figure 15 and 
3-2. PCR mutagenesis was used to create a BsmBI restriction enzyme recognition 
sequences at the each junctions between EGFP and ORF5a. Three regions were 
amplified by PCR as shown in Figure 17. The sizes of each PCR product are ~700 nts 
for EGFP ORF, ~ 1.2 kb for M ORF though start codon of 5a, and ~2.5 kb for the end of 
5a ORF through 3’ UTR of IBV including 14 nts of poly(A) tail was amplified. These 
PCR products were gel purified as described in the Materials and Methods and ligated to 
pSTBlue or pCR-XL-TOPO vectors resulting in three amplicon, pSTBGFP, pSBM and 
pCRB3’. pSTBlue cloning vector was used for pSTBGFP and pSBM construction 
except for the pCRB3 that used the pCR-XL-TOPO cloning vector. Three amplicons 
were amplified by maxi prep culture. 10 ug of pSBM and pCRB3’ were digested with 
XhoI restriction enzyme first and then ethanol precipitated for further digestion with 
BsmBI. pSTBGFP, pSBM and pCRB3’ were digested with BsmBI enzyme. Because  
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3 kb 
1.5 kb 
0.5 kb 
M        1       2       3 
FIG. 17. Site-directed mutagenesis by PCR. To replace the enhanced green 
fluorescent protein (EGFP) gene with ORF5a, BsmBI restriction enzyme recognition 
sequences were created by PCR on the EGFP ORF and an ORF5a neighboring 
sequence. These restriction enzyme sites will be further used to religate EGFP with 
ORF5a neighboring gene.  
M; 1 kb DNA ladder, lane 1; PCR product of EGFP, lane 2; PCR product from ORF 
M to start codon of ORF5a, lane 3; PCR product from 3’ end of ORF5a to 3’ UTR 
of IBV genome including the poly(A) tail. 
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pCRB3’ has an internal BsmBI recognition sequence, digestion of pCRB3’ with BsmBI 
produces two insert fragments. Inserts were separated from the vector by electrophoresis 
and purified from the gel after restriction enzyme digestion. These four fragments were 
ligated in one reaction. Because each BsmBI overhang has a unique sequence, 
theoretically the products can only be religated with the correct fragment. Furthermore, 
only the final ligation product with all the fragments having a pCR-XL-TOPO backbone 
can survive after transformation. Transformed plasmid constructs were verified by 
restriction enzyme digestion and the correct construct was named as pIBVG11. 
 Because the pIBVG11 construct only has the M ORF though 3’ UTR of IBV, 
further subcloning was performed using the pIBVG11 construct and amplicon P5 to 
produce P5 containing every structural genes as well as EGFP. Because pIBVG11 and 
P5 have the same orientation and M ORF has a unique BamHI restriction recognition 
sequence, both constructs were digested with BamHI. Then pIBVG11 was treated with 
phosphatase to prevent self-ligation. The larger fragment from P5 BamHI reaction 
containing the S ORF and part of the M ORF was replaced with a smaller fragment of 
pIBVG11 digested with BamHI. The ligation reaction was transformed into chemically 
competent cells and the recombinant GFP5 amplicon with EGFP instead of 5a were 
cloned. This GFP5 construct was sequenced using a primer upstream of 5a ORF to make 
sure there were no mutations during cloning. Sequences of EGFP and the upstream 
region of the ORF5a junction is shown in Figure 18. The EGFP ORF was replaced with 
ORF 5a exactly as intended. Furthermore, sequences, upstream of 5a and downstream of 
5a did not have any unintentional mutations. This shows that IBV infectious cDNA is  
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ORF5a and GFP start codon junction after ligation 
 
CAAAAACTTAACAAATACGGACGA TGGTGAGCAAGGGCGAGGAGCTGTTCAC 
GTTTTTGAATTGTTTATGCCTGCTACCA CTCGTTCCCGCTCCTCGACAAGTG 
 
 
 
 
 
 
 
 
 
 
FIG. 18. Sequence verification of EGFP ORF and ORF5a replacement. The start 
codon was denoted in a red box. B is the enlargement of part of A containing start 
codon. Prior to the start codon, sequences are identical as the intergenic sequences 
between ORF5a, the start codon is from EGFP. 
A 
B 
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very stable for further manipulation and subsequent serial cultures compared to the 
MHV infectious cDNA. 
 
Sequencing Analysis 
 After verifying sequences of the EGFP junction, it was assumed that there were 
no mutations introduced by PCR procedure because the PCR product was comparatively 
small and high fidelity thermostable polymerase developed for cloning of large PCR 
product was used to amplify the regions. After in vitro transcription and transfection, an 
infectious cDNA clone of IBV expressing EGFP could not be rescued. It was then 
decided to sequence the entire GFP5 amplicons and three nucleotide changes in 3’ UTR 
introduced by PCR were identified. The region with mutations was replaced with the 
same region of amplicon P5 and used to produce the infectious cDNA clones of 
recombinant IBV with the EGFP. 
 
In vitro Assembly 
Based on the experience acquired during development of the infectious cDNA 
clone of IBV, I used an orderly in vitro ligation approach for construction of the cDNA 
clone of IBV as described in chapter II. P1 and P2-1 were ligated and P2-2 and P3-1 
were ligated then P3-2 and P4 were ligated together and GP5L, and P5S were ligated. 
The larger ligation products from each of the four ligation reactions were separated by 
electrophoreses on agarose gels. The ligation products of P1/P21-1 and P2-2/P3-1 were 
ligated and ligation products of P3-2/P4 and P5 were ligated separately and without 
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further purification, these two ligation reactions were pooled and ligated overnight at 
16°C.  
 
In vitro Transcription and Electroporation 
Approximately 0.2 pM of cDNA template was used for an in vitro transcription 
reaction. To confirm that the in vitro transcript had a full-length RNA with the EGFP 
gene instead of ORF5a, a Northern blot analysis was performed using two different 
probes. One probe used was the same as that used for the 3’UTR of IBV for the 
infectious cDNA construction. The other probe was specific for EGFP. Because it has 
been shown that the N transcript increased the rescue of coronaviruses after transfection 
(56, 184, 201), N ORF transcripts were used as described in chapter II. 
 In vitro transcripts of IBVG cDNA and N ORF were electroporated into BHK-21 
cells. Because BHK-21 cells are not susceptible to IBV infection, Vero cells were 
overlaid on the electroporated BHK-21 cells. Two days after transfection, apparent CPE 
was noticed in the cells transfected with total cellular RNA from IBV infected cell and 
three days after transfection, CPE was noticed in the cells transfected with recombinant 
IBVG infectious cDNA. To confirm whether this recombinant virus expressed EGFP, 
the cells were examined under the UV microscope. As shown in Figure 19, the 
recombinant IBVG expressed EGFP that 5a was replaced with EGFP. RT-PCR was used 
to confirm the size difference of ORF 5a region.  
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FIG. 19. Recombinant infectious cDNA clone which 5a ORF was replaced with EGFP 
ORF was viable in infected cells and expressed EGFP. Cells transfected with 
recombinant infectious cDNA expressing EGFP. (A) Cells 3 days after transfection 
with the recombinant EGFP IBV transcript as viewed under a phase contrast 
microscope (B) Cells transfected with recombinant EGFP IBV transcript after 3 days 
transfection under an UV microscope.  
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DISCUSSION 
 Infectious cDNA clones of RNA viruses are one of the most powerful tools to 
study the function of viral proteins, especially during viral replication and viral 
assembly. The availability of infectious cDNA clones for many small RNA viruses has 
resulted in a tremendous development of RNA virus research. With the development of 
molecular biological techniques, it has been possible to construct infectious cDNA 
clones of coronaviruses overcoming the difficulties the large genome size and toxicity of 
the coronavirus genome in bacterial hosts. Several groups used three different 
approaches to construct infectious cDNA clones of coronaviruses, including MHV, 
TGEV, HCoV and IBV. These infectious cDNA clones have been developed to express 
foreign genes for potential gene expression system, gene transfer vector, and as vaccine. 
Infectious cDNAs of coronaviruses can be used to study the molecular biology of the 
viruses. Many studies have been done using defective interfering (DI) particle or 
targeted recombination in MHV and FIPV before the development of infectious cDNA 
clones. However, it is hard to conclude the result of mutants, especially deletion 
mutation studies, because of the extremely high rate of recombination during viral 
replication and transcription and the multiple crossovers during the recombination 
process. Therefore, using infectious cDNA clones is a more reasonable approach 
compared to using a targeted mutagenesis approach to study coronaviruses. 
  Coronaviruses have several small ORFs, some of these ORF are expressed in 
virus infected cells. However, the exact functions of these genes are not well understood. 
These small genes, referred as group specific genes, are not necessary for viral 
 100
replication in vitro in MHV, even though deletion mutant viruses of the region were 
significantly attenuated. IBV has four small group specific antigens including 3a, 3b, 5a 
and 5b.  
Previously, we were successful in constructing an infectious cDNA clone of the 
Vero cell adapted Beaudette strain of IBV. In this study, we wanted to use the infectious 
cDNA clone to resolve the issue of whether a small group specific antigen is necessary 
for the survival of IBV in vitro. One of the group specific genes, 5a ORF was replaced 
with green fluorescent protein. The C-terminal region of 5a protein was kept for the 
expression of 5b protein. After in vitro assembly and electroporation, a recombinant IBV 
5a deletion mutant of IBV expressing EGFP was successfully rescued and the 
fluorescence was observed. By sequence analysis and northern blot analysis, it was 
confirmed that there was no unintentional mutations in the amplicons used to construct 
the recombinant clone. Based on this study, 5a protein of IBV is not necessary for 
survival of IBV in vitro, even though the function of the protein is not yet understood. 
In our laboratory, group specific antigens of several different strains of IBV have 
been sequenced and shown that the proteins are conserved among different strains, 
especially putative 5a. Therefore, even though these proteins are not necessary for viral 
survival in vitro, it is possible that these proteins are important for viral replication in the 
natural host or maybe a protective protein against host defense mechanisms, such as 
cytokine mimicry molecules or anti-apoptotic proteins.  
 In summary, in this study, a recombinant infectious cDNA clone of IBV 
containing EGFP instead of 5a ORF was constructed. By sequence analysis of 
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amplicons, targeted mutagenesis was confirmed and the recombinant infectious cDNA 
was viable implying that the 5a protein is not necessary for IBV amplification in Vero 
cells. This also showed the possibility of using IBV as a gene transfer vector for poultry. 
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CHAPTER IV 
RECOMBINANT SEMLIKI FOREST VIRUS REPLICON CAN BE PACKAGED 
INTO IBV VIRIONS WITHOUT IBV CIS ACTING SIGNAL SEQUENCE 
 
INTRODUCTION 
Infectious bronchitis virus (IBV) has been a recognized problem in the poultry 
industry since 1931 (158). IBV has been controlled by traditional attenuated live vaccine 
strategies. The high mutation rate and the high frequency of recombination of IBV, 
however, has made it necessary to seek alternative methods which can control the disease 
more effectively and to lower the possibility of emerging recombinant IBV originating 
from field and vaccine strains (reviewed in (39)).  
IBV belongs to the order Nidovirales in the Coronaviridae family. Coronaviruses 
cause clinical disease in a number of animals, including humans (34, 126). Most 
coronaviruses cause disease only in the species from which they were isolated and, if 
they replicate in cell culture, predominantly replicate only in cell lines derived from their 
natural hosts (197). IBV has four known structural proteins, including the spike 
glycoprotein (S) that is post-translationally cleaved into S1 and S2, the integral 
membrane glycoprotein (M), the small membrane protein (E) and the nucleocapsid 
protein (N) (94). S, M, and E proteins are envelope proteins that are embedded in the 
host-derived bilipid layer of the viral envelope. The S protein is not required for virus 
budding process but is responsible for viral attachment and entry, determining host 
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specificity and creating the binding site for cellular receptors. Receptors for MHV, 
TGEV and HCoV have been identified (46, 54, 77, 136, 200). Determinants responsible 
for the generation of neutralizing antibodies also lie on N terminal of the S protein, 
especially S1 (40, 81, 84, 183).  
Both M and E proteins localize in the cis-Golgi compartment and several studies 
have suggested that the M and E proteins are critical for intracellular viral budding (47, 
50, 98, 118). Expression of the E proteins of MHV and IBV, in the absence of other viral 
proteins, produces vesicles that can be released from the cells (47, 120). However, co-
expression of M and E are necessary in TGEV and bovine coronavirus (BoCV) to make 
virus like particles (VLP) (13, 17, 193). The N protein binds to the viral RNA genome, 
producing the ribonucleoprotein complex (10, 43, 125, 130, 144). The N protein is the 
only viral protein that is phosphorylated and the phosphorylation of the N protein has 
been implicated as having a role in viral RNA and protein interaction.  
Packaging mechanisms of several coronaviruses, such as MHV, BoCV and more 
recently TGEV have been studied (44, 60, 124). MHV packages only viral genomic 
RNA, whereas IBV and BoCV have been shown to package not only genomic RNA, but 
also subgenomic RNAs (204). Using defective interfering (DI) RNA and deletion 
mutagenesis, Makino et al. have located packaging signal sequences in MHV and shown 
that M protein and packaging signal sequence interaction might mediate specific viral 
genomic RNA packaging into MHV virions (124, 129). The BoCV packaging signal 
sequence was identified based on a sequence homology search of BoCV genome with 
the MHV packaging signal sequence (44). In the presence of the packaging signal 
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sequence, non-viral RNA can be packaged into BoCV or MHV virions, respectively. 
However, it is interesting that one of the naturally occurring BoCV DIs, Drep can be 
packaged into BoCV virions without the known packaging signal sequence (44). 
Recently, the packaging signal sequence of TGEV has been identified by Escobars et al. 
(60). They also showed that highly purified TGEV only packaged genomic RNA like 
MHV and the packaging signal sequence is located within the 649nts at the 5’ UTR of 
TGEV genomic RNA (60). In the study, it was suggested that not only the packaging 
signal sequence itself, but also viral replication status, is important for efficient viral 
packaging in TGEV.  
Semliki forest virus (SFV), a prototype of the alphavirus genus and a member of 
the Togaviridae family, has a single-strand, positive sense RNA genome (160). Several 
members of this group, in particular Sindbis virus (SIN), SFV, and Venezuelan equine 
encephalitis (VEE) virus, have provided valuable tools for understanding virus structure 
and replication. The two alphaviruses most extensively studied in laboratories, SIN and 
SFV, are generally considered avirulent for humans. The alphavirus genome is 
approximately 11.7 kb and is encapsidated within an icosahedral capsid protein (177). 
Cells infected with these viruses synthesize abundant amounts of viral genomic RNA 
and subgenomic RNA. The genomic and subgenomic RNAs are 5' capped and 3' 
polyadenylated (27). The 5’ two thirds of the genomic RNA encode the replicase 
polyproteins, which are cleaved to produce nsP1, nsP2, nsP3 and nsP4 products. The 
subgenomic RNA is identical in sequence to the 3' one-third of the genomic RNA and 
encodes the structural proteins. These include the capsid protein, which interacts with 
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the genomic RNA to form the viral nucleocapsid and two membrane glycoproteins 
(reviewed in (177)). Cytoplasmic replication of the genomic and subgenomic RNAs is 
mediated by the replicase gene using a full-length negative sense RNA as a template.  
The viral structural proteins are translated from the subgenomic mRNA as a polyprotein 
that is processed into the individual virion components by a viral protease. 
Specific genomic RNA packaging of alphaviruses has been shown to depend on 
the packaging signal sequence that is present only on the genomic RNA. The signal 
sequences of SIN, SFV and Ross river virus (RRV) have been identified and used to 
make replicon vectors that can replicate and be packaged into virions produced by a 
helper construct. The helper construct encodes viral structural genes under the control of 
the subgenomic RNA promoter. Because the helper construct lacks the packaging signal 
sequence, it results in aberrant self-packaging, in spite of its high concentration in the 
cytoplasm during viral replication and transcription. The replicon, packaged into the 
newly made virions, can infect cells and replicate, but the progeny RNAs cannot be 
transmitted into new cells because they lack the viral structural proteins.  
As an alternative to live attenuated vaccines, we were interested in developing a 
new type of vaccine by combining the advantages of two different viruses, IBV and SFV. 
In this study, as a prerequisite of this purpose, we decided to develop recombinant SFVs as 
a tool for identifying the packaging signal sequence of IBV. The SFV replicon can be 
replicated in the cytoplasm to produce high concentrations of this RNA. We hypothesized 
that if a recombinant SFV has the packaging signal sequence of IBV, the replicon can be 
packaged into an IBV virion. To our surprise, however, with or without any candidate 
 106
packaging signal sequence of IBV, rSFV can be packaged into an IBV virion suggesting 
IBV virion can be a useful candidate for pseudotyping of SFV vectors for specific 
targeting to respiratory system of poultry as a vaccine or for gene transfer.  
 
MATERIALS AND METHODS 
Viruses and Cells  
A Vero cell culture adapted Beaudette strain of IBV was obtained from 
American Type Culture Collection (ATCC, Manassas, VA) and then plaque purified 
three times in the laboratory before use. The virus was propagated in the African green 
monkey kidney Vero cell line obtained from the ViroMed Laboratory (Minnetonka, 
MN) and maintained in Dubecco’s modified Eagle medium (DMEM) containing 5% 
fetal bovine serum (FBS) supplemented with penicillin G (100 unit/ml) and streptomycin 
(100 ug/ml).  
 
RNA Preparation 
Viral RNA was prepared from the supernatant of IBV infected Vero cells. 
Briefly, Vero cells were infected with 0.1 multiplication of infection (m.o.i) and 
incubated in a CO2 incubator at 37°C until the cells showed more than 80% 
cytopathogenic effect (CPE), such as syncytia formation. The cells showing extensive 
CPE were frozen and thawed three times and then cell debris was removed by 
centrifugation at 3,000 rpm using a tabletop centrifuge (CR 412; Jouan Inc. Winchester, 
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VA). The supernatants were then ultracentrifuged at 35,000 rpm for 2 hours at 4°C using 
an L7-55 ultracentrifuge (Beckman, Palo Alto, CA) with an SW55Ti swing bucket rotor 
to pellet the virus. The viral pellet was re-suspended in small volumes of TEN (10 mM 
Tris-Cl, pH 8.0, 1 mM ethylendiaminotetraacetate (EDTA), pH 8.0 and 0.1M NaCl) 
buffer. 
TRIZOL reagent (Invitrogen, Carlsbad, CA) was used to extract the RNA from 
the re-suspended viral pellet following by the manufacturer’s instruction. Briefly, 1 ml 
of TRIZOL reagent was added to 200 ul of viral pellet suspension in TEN buffer and 
then mixed thoroughly by inverting the microfuge tube several times. The mixture was 
incubated for 5 minutes at room temperature before adding 200 ul of chloroform and 
mixing thoroughly. The mixture was then incubated at room temperature for 3 minutes. 
To separate the aqueous and the organic phases, the mixture was centrifuged at 12,000 
rpm for 15 minutes at 4°C using a microcentrifuge 5417 R (Eppendorf, Hamburg, 
Germany). The upper (aqueous) phase was then transferred to a new nuclease free 
microfuge tube and a 500 ul of isopropanol were added to precipitate the RNA. After a 
10-minutes incubation at room temperature, the RNA was pelleted by centrifugation at 
12,000 rpm for 15 minutes at 4°C. Before suspending the RNA pellet with nuclease free-
water, the RNA pellet was washed with 70% ethanol, and then briefly air-dried. The 
RNA solution was quantified using a SmartSpec TM 3000 spectrophotometer (BIO-RAD, 
Hercules, CA) and stored at –70°C until further use as a template for RT-PCR or as a 
size marker for electrophoresis. 
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RT-PCR and PCR Amplification of Target Genes 
The 3’UTR, 5’UTR, 1b region of DI 61(175) and bovine coronavirus packaging 
signal sequence homologous region of IBV (44) were cloned by RT-PCR. Sequences 
and locations of primers used in this study are listed in Table 4. The first cDNA reaction 
was done using the SUPERSCRIPTTM First-Stranded Synthesis System for RT-PCR 
(Invitrogen, Carlsbad, CA) according to manufacture’s directions. Briefly, 1-2 ug of 
RNA in 8 ul of nuclease free water with 1 ul of 10 mM deoxynucleotide-triphosphate 
(dNTP) and 10 pM of each reverse primer BE5R, IBVPR, and CPR were incubated in a 
70°C water bath for 5 minutes. Reactions were chilled on ice for 5 minutes before 
adding 2 ul of 10X first strand buffer, 4 ul of 25 mM MgCl2, 0.1 M dithiothreitol (DTT), 
1 ul of RNase inhibitor, (50 units/ul, Invitrogen) and then incubated at 42°C for 50 
minutes after adding 1 ul of Superscript reverse transcriptase (50 Units/ul). The reaction 
was terminated by incubating at 75°C for 15 minutes before degrading RNA template 
with 1 ul of E. coli RNase H (2 Units/ul), and incubating for 20 minute at 37°C.  
Two ul of each completed reverse transcription reaction was used as a template 
for PCR reaction. A 50 ul reaction included 6 ul of 25 mM MgCl2, 1 ul of 10 mM 
deoxynucleotide triphosphate (dNTP), 5 ul of PCR buffer A (Promega, Madison, WI) 
and 1 ul each of 10 pM of forward and reverse primer, and 0.5 ul of Taq polymerase (5 
unit/ul, Promega) and distilled water was added to bring the total reaction volume to 50 
ul. The BE5R and IBVLF oligos were used as forward and reverse primers, respectively 
for 5’ UTR RT-PCR amplification. The IBVPR and IBVPF primer pair were used for 
amplification of the region homologous to the bovine coronavirus packaging signal  
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TABLE 4. Primer pairs used for RT-PCR or PCR amplification and sequencing of 
recombinant SFV replicons 
 
 
 
 
Name position Sequence polarity 
IBVLF 1-26 5’ ACTTAAGATAGATATTAATATATATC 3’ + 
BE5R 528-561 5’ GGGAGATACTCCCTGTTTTAG 3’ _ 
IBVPF 18821-18843 5’ AAATGGCCTAGTAGTTCTGTATG 3’ + 
IBVPR 19115-19139 5’ ATACCTTTCTACAAAACTCTCCTC 3’ _ 
CPF 18200-18224 5’ CCTAAATTTGACCGCATTAGCTTCC 3’ + 
CPR 18486-18510 5’ CAATATTGTCGATAGACTGGAGAGC 3’ _ 
EGFPF2  5’ GGATCCCAAGGGCGAGGAGCTGTTC 3’ + 
EGFPR  5’ GGATCCTTACTTGTACAGCTCGTC C 3’ _ 
SFVR 7440-7466 5’ GGCGCCACCGGCGGCCGTAAAACGTC 3’ _ 
nsP4F 5761-5780 5’ CGGTGGTGGACAGGCTCACA 3’ + 
nsP4R 6001-6200 5’ TCTGTCCAAGCAACTATCCG 3’ _ 
 110
sequence. CPR and CPF primers were used to amplify the 1b region of CD-61. Reaction 
conditions included an initial denaturation at 94°C for 5 minutes followed by 30 cycles 
of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds and an 
elongation at 72°C for 30 minutes. The final step was an elongation at 72°C for 10 
minutes. 10 pM of each forward and reverse primer, GFPF2, and EGFPR with 50 ng of 
pLEGFP-N1 vector as a template were used for EGFP PCR amplification. For the PCR 
reaction condition, the same condition described previously was used except for the 
primer sets. PCR amplification conditions included initial denaturation at 94°C for 5 
minutes followed by 30 cycle of denaturation at 94°C for 30 seconds, annealing at 55°C 
for 30 seconds and elongation at 72°C for 40 seconds. This was followed by 7 minutes 
incubation at 72°C for the final elongation.  
 
Cloning and Construction of Recombinant SFV Replicons 
 PCR products were run on 0.7% agarose gels in Tris-acetate-EDTA (TAE) buffer 
containing ethidium bromide (EtBr). DNA bands of appropriate size were excised from 
the gels on UV transilluminator and the PCR products from the gels were purified using 
a QUIAquick Gel Extraction Kit (QIAGEN Inc. Valencia, CA) following the 
manufacture’s directions. The concentration of gel purified PCR products was measured 
with a SmartSpec 3000 spectrophotometer (BIO-RAD). Each PCR product was ligated 
into a cloning vector, pSTBlue (Novagen, Darmstadt, Germany) using T4 DNA ligase 
(Promega). Equal-molar ratios of insert and vector were incubated for 2 hours at 16°C 
and then transformed into chemically competent NovaBlue cell by the heat shock 
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method. Transformed bacteria were plated on Luria-Bertani (LB) medium agar plates 
containing 50 ug/ml ampicillin and grown overnight at 37°C. Each colony was grown 
overnight in LB media for mini preparation of plasmids. Plasmid prepared by the alkali 
lysis method and insert size and direction were confirmed by restriction enzyme 
digestion and nucleotide sequencing. pGEBN-1 described in chapter II was used to 
subclone the 3’UTR of IBV. 
To subclone EGFP as a reporter gene into pSFV-1, pSFV-1 and pSTBEGFP 
plasmids were digested with BamHI followed by CIP treatment of pSFV-1 to prevent 
self-ligation. The small DNA fragment of the pSFTBEGFP BamHI digestion reaction 
was separated from the vector by running in a 0.7% agarose gel and the insert was 
purified with the gel extraction kit (QIAGEN) following manufacturer’s directions. An 
equal-molar ratio of pSFV-1 and the EGFP insert were ligated overnight and 
transformed into Oneshot chemically competent cells (Invitrogen, Carlsbad, CA). The 
plasmids were prepared from the overnight mini culture of the colonies and plasmid 
having correct orientation of the EGFP gene downstream of SFV subgenomic promoter 
in the correct frame was confirmed by restriction enzyme digestion and nucleotide 
sequencing. 
 Candidate packaging signal sequences were subcloned downstream of EGFP in 
pSFGFP. pSFGFP was digested with SmaI restriction enzyme and then CIP treated to 
inhibit self-ligation. Amplicons containing 5’ UTR, 3’ UTR, ORF1b region and the 
BoCV packaging sequence homologous region were digested with EcoRI to excise the 
inserts from the vectors. Inserts were gel purified by agarose gel electrophoresis and to 
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make the ends blunt, the inserts were treated with T4 DNA polymerase (Promega). 
These prepared DNA inserts were phosphorylated using T4 DNA kinase (Promega) then 
ligated to pSFEGFP vector prepared by SmaI digestion and subsequent phosphatase 
treatment.  
 
Nucleotide Sequencing 
Each replicon DNA was prepared from transformed bacterial cultures grown 
overnight and DNA templates were prepared using Mini Prep kits (QIAGEN Inc., 
Valencia, CA). Sequencing was performed using the ABI prism BigDye Terminator 
Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA). A 
standard sequencing reaction included 350-500 ng of plasmid DNAs mixed with 2 ul of 
Bigdye mixture (ABI) and 10 pM of primers. The remainder of the reaction mixture was 
adjusted to 6 ul with distilled water. Sequencing reactions were performed using a 
GeneAmp thermocycler (PerkinElmer) according to manufacturer’s suggestion including 
a pre-denaturation at 96°C for 2 minutes and 30 cycles of 96°C for 30 seconds, 52°C for 
15 seconds and 60°C for 4 minutes. Non-incorporated nucleotides were removed using 
micro Bio-spin chromatography columns (BIO-RAD, Hercules, CA) and completely 
dried using a vacuum drier. Completed sequencing reactions were sent to the Gene 
Technology Laboratory in the Department of Biology at Texas A&M University. 
Sequences were read using an ABI automatic sequencer 3100 (ABI, Foster City, 
California).  
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Analysis of Sequence  
Sequence data were analyzed using SDS Biology Workbench 
(http://workbench.sdsc.edu) (San Diego Supercomputer Center, University of California, 
San Diego, CA). The LALIGN program was used for DNA and amino acid sequence 
comparison. The TACG program was used to search for restriction enzyme digestion 
profiles for the purpose of subcloning. The SIXFRAME program was used to translate 
the DNA sequence into the amino acid sequence. The MFOLD program 
(http://bioweb.pasteur.fr/seqanal/interfaces/mfold-simple.html) was used to compare 
RNA secondary structures. 
 
In vitro transcription 
 Capped runoff SP6 transcripts were synthesized in vitro from each recombinant 
SFV plasmids that were linearized by SpeI restriction digestion (Promega). Digested 
plasmids were phenol:chloroform extracted and then ethanol precipitated. Precipitated 
DNA was dissolved with diethypyrocarobonate (DEPC) treated water. 1.5 ug of template 
was used for each transcription reaction. In vitro transcription was performed using SP6 
RNA polymerase (Invitrogen, Carlsbad, CA) following the transcription reaction 
directions described for the SFV-1 expression vector (Invitrogen). Briefly, 50 ul of 
transcription reaction consisting of 5X SP6 Buffer (0.2M Tris-HCl pH 7.9, 30 mM 
MgCl2, 10 mM spermidine- (HCl)3), 20 ul of 2 NTP mix containing 2.5 mM ATP, 2.5 
mM CTP, 2.5 mM UTP, 1.25 mM GTP, 5 ul of 10 mM capping analog, 10 mM DTT, 2 
ul of recombinant ribonuclease inhibitor (40 units/ul) and 38 units of SP6 RNA 
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polymerase and the remaining reaction was filled with DEPC treated water. The 
transcription reaction was performed at 37°C for 2 hours and followed by DNase I 
digestion to remove template DNA. The transcripts were precipitated with isopropanol 
and washed with 70% ethanol. The transcripts were resuspended in DEPC treated water 
and then the concentration of the transcripts was measured using a SmartSpec TM 3000 
spectrophotometer (BIO-RAD, Hercules, CA) before storing at –70°C until used for 
transfection. 
 
Transfection and Infection  
DMRIE-C reagent (Invitrogen) was used for RNA transfection following the 
manufacturer’s instructions. Five ug of in vitro transcribed RNA was used for 
transfection of cells in each 30 mm cell culture dish. Vero cells were seeded in six wells 
plates the day before transfection. The Vero cells were washed with phosphate buffered 
saline twice and 2 multiplicities of infection (m.o.i) of IBV Beaudette strain were added 
for 1 hour at 37°C. After adsorption, the cells were washed twice with PBS and then 
transfected with each replicon transcript. The infected cells were washed once with 2 ml 
of serum free media OPTI-MEM (Invitrogen) per well. Five ug of each transcript was 
suspended in 1 ml of OPTI-MEM containing 10 ul of DMRIE-C reagent. The reaction 
was thoroughly mixed by briefly vortexing and then overlaid on the Vero cells. After 
four hours incubation, medium was replaced with complete DMEM containing 10% 
FBS and further incubated for 16 more hours. 
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RNaseA and Antibody Treatment 
Hyper-immune serum from chicks infected with IBV Beaudette strain was kindly 
provided by Dr. King (USDA, Southeast Poultry Research Laboratory, Athens, GA). 
The neutralizing titer of the antibody was determined. The antibody was two fold 
serially diluted with DMEM. One hundred plaque forming units (PFU) of IBV in 200 ul 
of DMEM was prepared by diluting viral stock with DMEM. Serial two-fold diluents of 
antibody and 100 PFU of IBV were incubated at 37°C for 30 minute and the mixture 
was overlaid on six well plates seeded with monolayers of Vero cells. After five days 
incubation, antibody titer was measured as the lowest dilution factor that completely 
neutralized plaque formation. 
 Passage 0 (P0) supernatants were treated with RNase A or neutralizing antibody 
before passage 1 (P1). A 500 ul aliquot of each passage 0 supernatant was incubated 
with a 2 fold dilution of antibody or 20 ul of RNase A (10 mg/ml), for 30 minutes at 
37°C. A control was similarly incubated without serum or RNaseA. After incubation, the 
supernatants were inoculated onto fresh Vero cells seeded on 35 mm cell culture petri 
dish as passage 1.  
 
Northern Blot Analysis 
 
Preparation of a random primed isotope labeled probe. 
 Three different probes were used in this study to differentiate coronavirus 
subgenomic RNAs, SFV genomic RNA, GFP, genomic and subgenomic RNA of 
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recombinant SFV containing GFP. pGEBN-1 that is described in chapter II was used as 
a probe specific to the genomic and subgenomic RNAs of IBV. pGEGFP described in 
chapter III was used as a specific probe against GFP in recombinant SFV genomic RNA 
and subgenomic RNA. Part of nsP4 of pSFV was PCR amplified and cloned into pGEM 
vector and used as a specific probe against SFV genomic RNA. To prepare random 
primed probes, each amplicon was digested with PstI restriction enzyme and then 
phenol:chloroform extracted followed by ethanol precipitation to remove contaminating 
RNase. One ug of template was used for an in vitro transcription and labeling using T7 
RNA polymerase (Promega). Briefly, 4 ul of 5X transcription buffer, 2 ul of 100 mM 
DTT, 1 ul of RNase inhibitor (Promega, 30 unit/ul), 4 ul of rNTP mix (2.5 mM rCTP, 
rATP, and rGTP, 1.2 ul of 200 uM rUTP, 5 ul of [α-32P] rUTP) and 1.3 ul of T7 RNA 
polymerase (20 units/ul) were used in a 20 ul reaction. The reaction was incubated at 
37°C for 1 hour and then ethanol precipitated. The probe was resuspended in deionized 
formamide and stored at –20°C. Radioisotope activity was measured with a liquid 
scintillation system (Beckman coulter Inc., Fullerton, CA) before using for hybridization 
reaction.  
 
RNA transfer 
To transfer RNAs to a nylon membrane for northern hybridization analysis, less 
than 5 ug of each total cellular RNAs was prepared from each sample and 
electrophoresed on a denaturing agarose gel containing formaldehyde following the 
standard method (153) with the following modifications; RNAs were denatured with 
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sample buffer with 1/10 v/v formaldehyde gel–running buffer (0.2M 3-(N-norpholino) 
propanesulfonic acid (MOPS) (pH 7.0), 80 mM sodium acetate and 10 mM EDTA (pH 
8.0)), 1/5 v/v of formaldehyde, 1/2 v/v of deionized formamide, 2 ug of EtBr, and 1/10 
v/v of formaldehyde gel-loading buffer (50% glycerol, 0.25% bromophenol blue, 0.25% 
xylene cyanol FF) per RNA sample containing a total 15 ul of reaction volume. RNAs 
and sample buffer were mixed and then denatured at 70°C for 5 minute and chilled on 
ice. Then, a 1% denaturing agarose gel was prepared with a 1/10 volume of 10 X 
formaldehyde gel running buffer and formaldehyde to give final concentration of 2.2 M 
formaldehyde. Each RNA sample was loaded on the agarose gel and run at 90 V in 1 X 
formaldehyde gel-running buffer. After one hour, the buffer from each reservoir was 
collected, mixed and returned to continue the electrophoresis. When the xylene cyanol 
dye front was at the bottom of the gel, electrophoresis was terminated. The gel was 
washed several times with distilled water and then soaked in 0.05N NaOH for 20 
minutes and exposed to long wavelength UV light for 60 seconds. The gel was then 
washed with distilled water and soaked for 20 minutes in 10 X sodium chloride sodium 
citrate (SSC) buffer. RNA from the gel was transferred to a nylon membrane by 
capillary transfer in 10 X SSC overnight. RNA transfer was confirmed by EtBr staining 
of the nylon membrane and the molecular weight controls were marked with a pencil. 
The membrane was then fixed by UV cross-linking for 30 seconds with GS gene linker 
UV chamber (BIO-RAD).  
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Hybridization reactions 
Duplicate or triplicate nylon membranes with the same samples were prepared 
and hybridized with different probes at the same time. The nylon membranes were 
hybridized with a different specific probe having specific activity of 2 x 107 cpm/ug that 
was α-32P labeled. Hybridization reactions were performed using an autoblot 
hybridization oven (Bellco Glass Inc., Vineland, NJ). Hybridization conditions included 
incubation at 55°C for 12 hours in hybridization buffer containing 50% deionized 
formaldehyde, 2 X Denhardt’s reagent, 5 X SSC and 0.1% SDS. After hybridization, 
excess probe was removed by washing with buffer containing 1 X SSC, 0.1% SDS, 
followed by three washes for 20 minutes each at 68°C in 0.2 X SSC and 0.1% SDS. 
After hybridization, the nylon paper was exposed to an image plate (IP) for 20 minutes 
to one hour depending on the signal intensity. The image was analyzed using a BAS-
1800 II phosphoimage reader (Fusifilm Electronic Imaging Ltd. Tokyo, Japan) and 
analyzed using the Image gauge V3.12 and L processor V1.72 programs. 
 
RESULTS 
 
RT-PCR and Cloning 
 Based on a study which has shown that the IBV virion can package genomic 
RNA, as well as subgenomic RNA (38), I hypothesized that there must be more than one 
packaging signal sequence in IBV. To identify the packaging signal sequence, I selected 
several regions as putative packaging signal sequences of IBV based on several studies. 
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The 5’ and 3’ untranslated region of the IBV have been shown to be important for viral 
replication and transcription (48). Based on a study by Penzes et al, part of the ORF1b 
region in DI, CD-61 was selected as a candidate for a packaging signal sequence of IBV 
(140). CD-61 can be efficiently packaged into IBV virions. Another candidate signal 
sequence was selected after a homologous sequence search with bovine coronavirus 
signal sequences using the same approach as that used by Cologna et al. (44) to identify 
the packaging signal sequence of BoCV. The result was that only one candidate gene in 
IBV showed homology with BoCV and shared a similar location as the BoCV packaging 
signal. Packaging signal sequences of MHV, BoCV and putative candidate packaging 
signal sequence of IBV were compared in Figures 20 and 21. These four candidates 
genes were RT-PCR amplified using total cellular RNA prepared from IBV infected 
cells.  
The MHV packaging signal sequence was identified by deletion mutation studies 
using DIs of MHV (124). We considered using a DI system to find the packaging signal 
sequence of IBV, but we rationalized that the interpretation of data in a DI system would 
be complex, especially if there was more than one packaging signal sequence for IBV. 
Therefore, we chose the more straightforward approach of constructing a system that can 
replicate by itself, while containing only one cis signal sequence of IBV per construct. 
We decided to use the SFV vector as the RNA expression system because it can replicate 
by itself in the absence of the IBV replicase. Furthermore, SFV only replicates in the 
cytoplasm so its recombinant RNA can be carried by the IBV virion in the presence of a 
packaging signal sequence.  
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 ALIGN calculates a global alignment of two sequences 
BCV-pack                                            290 nt vs. 
MHV-packaging                                       291 nt 
scoring matrix: DNA, gap penalties: -16/-4 
73.3% identity; Global alignment score: 722 
 
 
 
            10        20        30        40        50           
BCV  AATGGCGTAGTGGTGGACAAGGTTGGAGACACAGATTGTGTGTTTTATTTTGCTGTGCG- 
     ::::::::::: ::::: :: ::::::::  : :::   :  ::::  :::::::::::  
MHV  AATGGCGTAGTTGTGGAGAAAGTTGGAGATTCTGATGTGGAATTTTGGTTTGCTGTGCGT 
             10        20        30        40        50        60 
 
    60        70        80        90       100       110          
BCV  AAAGAGGGTCAGGATGTCATCTTCAGCCAATTCGACAGCCTGAGAGTCAGCTCTAACCAG 
     ::::: ::: : ::::: ::::::::::     :  :::::   :   :::  : ::: : 
MHV  AAAGACGGTGACGATGTTATCTTCAGCCGTACAGGGAGCCTTGAACCGAGCCATTACCGG 
             70        80        90       100       110       120 
 
   120       130       140       150       160       170          
BCV  AGCCCACAAGGTAATCTGGGGAGTAATGAACCCGGTAATGTCGGTGGTAATGATGCTCTG 
     ::::::::::::::::::::  :::::      ::: :: :: : :::::::: :::::  
MHV  AGCCCACAAGGTAATCTGGGTGGTAATCGCGTGGGTGATCTCAGCGGTAATGAAGCTCTA 
            130       140       150       160       170       180 
 
   180       190       200       210        220       230         
BCV  GCAACCTCCACTATCTTTACACAAAGCCGTGTTATTAGC-TCTTTTACATGTCGTACTGA 
     ::      :::::::::::: :::::: :  :::::: : ::::: :::  :::  : :: 
MHV  GCGCGTGGCACTATCTTTACTCAAAGCAGA-TTATTATCCTCTTTCACACCTCGATCAGA 
            190       200       210        220       230          
 
    240       250       260       270       280       290 
BCV  TATGGAAAAAGATTTTATAGCTTTAGATCAAGATGTGTTTATTCAGAAGTAT 
      ::::: ::::::::::: : ::::::: : :::::::: :::   :: ::: 
MHV  GATGGAGAAAGATTTTATGGATTTAGATGATGATGTGTTCATTGCAAAATAT 
   240       250       260       270       280       290  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 20. Sequence alignment of MHV and BoCV packaging signal sequences. 
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ALIGN calculates a global alignment of two sequences 
 version 2.0uPlease cite: Myers and Miller, CABIOS (1989) 4:11-17 
BCV-pack                                            290 nt vs. 
ibv-pack                                            319 nt 
scoring matrix: DNA, gap penalties: -16/-4 
53.9% identity; Global alignment score: 74 
 
 
                 10           20        30        40        50       
BCV     -AATGGCGTAGTGGT---GGACAAGGTTGGAGACACAGATTGTGTGTTTTATTTTGCTG- 
         :::::: :::: ::   : :  : : : :: :    ::::    :: :: : ::::::  
ibv     AAATGGCCTAGTAGTTCTGTATGATGATAGATATGGTGATTACCAGTCTTTTCTTGCTGC 
                10        20        30        40        50        60 
 
           60         70              80         90       100        
BCV     TGCGAAAGAGGGTC-AGGATGT-CA-----TCTTCAGCCA-ATTCGACAGCCTGAGAGTC 
        ::  :: :  : :: ::  : : ::     :  : ::: : :::   ::  :  :::    
ibv     TGATAATGCTGTTCTAGTTTCTACACAGTGTTATAAGCGATATT---CATACGTAGAAAT 
                70        80        90       100          110        
 
        110        120          130           140        150         
BCV     AGC-TCTAACCAGAGCC--CACAA-GGTA----ATCTGGGGA-GTAATGAACCCGG---- 
        : : :::::   :  :   :: :: ::::    ::     :: : :  ::::: :      
ibv     ACCATCTAATTTGCTCGTTCAGAATGGTATGCCATTAAAAGATGGAGCGAACCTGTATGT 
        120       130       140       150       160       170        
 
           160       170       180             190       200         
BCV     TAATGTCGGTGGTAATGATGCTCTGG-----CAACCTC-CACTATCTTTACACAAAGCCG 
        : ::    ::: ::::: :::  : :     : ::::  ::: ::    :: ::  : :: 
ibv     TTATAAGCGTGTTAATGGTGCGTTTGTTACACTACCTAACACAATAAACACCCAGGGTCG 
        180       190       200       210       220       230        
 
        210       220       230       240       250       260        
BCV     T-GTTATTAGCTCTTTTACATGTCGTACTGATATGGAAAAAGATTTTATAGCTTTAGATC 
          ::::: :   :::::  :  ::::: ::: :: ::    :::::: : ::: :      
ibv     AAGTTATGAAA-CTTTTGAACCTCGTAGTGACATTGAGCGTGATTTTCTCGCTATGTCAG 
        240        250       260       270       280       290       
 
        270       280       290 
BCV     AAGATGTGTTTATTCAGAAGTAT 
        : ::    ::: :  : : :::: 
ibv     AGGAGAGTTTTGTAGAAAGGTAT 
         300       310          
 
 
 
 
 
 
 
 FIG 21. Sequence alignment of BoCV packaging signal sequence and the putative 
IBV homologue. 
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We decided to use enhanced green fluorescence protein (EGFP) as a reporter 
gene in order to verify transfectant replication by UV microscopy before northern 
analysis. The overall constructs of recombinant SFV replicons are illustrated in Figure 
22. EGFP was PCR amplified using a primer pair containing a BamHI restriction 
enzyme recognition sequence at both the 3’ and 5’ ends, because the pSFV-1 expression 
vector has only one cloning site, a BamHI restriction enzyme recognition sequence that 
contains an internal start codon to express the recombinant protein. The genuine start 
codon of EGFP was removed and the 5’ sequence of EGFP was mutated by PCR 
mutagenesis to use the SFV vector start codon. The EGFP PCR product was cloned into 
a TA-PCR cloning vector, pSTBlue (Novagen). The EGFP gene was cut from the 
cloning vector and then subcloned into SFV-1 digested with BamHI. The direction of 
EGFP ORF in SFV-1 was verified by PCR amplification using primer sets EGFPF and 
SFVR as forward and reverse primers, respectively. The recombinant SFV construct 
with EGFP in the proper orientation was named pSFGFP. Before subcloning the 
candidate packaging signal sequences into pSFGFP, expression of EGFP from the 
construct was confirmed by transfection of the construct into BHK-21 and Vero cells. 
The four RT-PCR amplified candidate IBV packaging signal sequences were cloned into 
pSTBLUE (Novagen) for further amplification and subcloning into pSFGFP. Except for 
a BamHI site that was used for the cloning of EGFP, pSFGFP has only one cloning site, 
SmaI. pSFGFP was digested with SmaI and treated with phosphatase to inhibit self-
ligation of the vector. Each candidate sequence was digested from the cloning vector 
using EcoRI and each end was blunted using T4 DNA polymerase. Each candidate 
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pSFV-1  
 
 
 
 
 
pSFGFP 
 
 
 
 
 
pSFGPS 
 
 
 
pSFGF5UTR 
 
 
 
 
 
pSFGF3UTR 
 
 
 
 
 
pSFGFCPS 
nsP1 nsP2 nsP3 nsP4
GFnsP1 nsP2 nsP3 nsP4
GFnsP1 nsP2 nsP3 nsP4
GFnsP1 nsP2 nsP3 nsP4
GFnsP1 nsP2 nsP3 nsP4
GFnsP1 nsP2 nsP3 nsP4
BamHI 
cloning site 
FIG. 22. Schematics of pSFV-1 eukaryotic expression vector and recombinant SFV 
replicons constructed using pSFV-1 vector. The reporter protein, EGFP was denoted as 
green boxes. The 3’ and 5’ untranslated region of SFV were denoted with gray boxes. 
Each candidate packaging sequence was marked with different colors. Small boxes in 
front of EGFP represent subgenomic promoter sequence of SFV. 
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packaging signal sequence was cloned downstream of EGFP. The direction of each 
candidate sequence in pSFGFP was analyzed by RT-PCR using the forward primer used 
to clone each gene and SFVR as a reverse primer. Sequencing reactions and analysis 
were performed to confirm the sequence and direction of each construct using SFVR. 
Each construct was named as illustrated in Figure 22. The construct with a homologous 
sequence of the BoCV packaging signal sequence was named pSFGPS and the construct 
having a sequence 1b region of DI was named pSFGFCPS. The other two constructs 
having 3’ and 5’ UTR sequences were referred to as pSFGF3’UTR and pSFGF5’UTR, 
respectively. 
Three different probes were used for northern blot analysis. To identify the 
replication and transcription of IBV, a probe against the 3’UTR of IBV was used that is 
described in chapter II. To identify the replication and transcription of each SFV 
replicon, a probe against EGFP was used as described in chapter III. To differentiate the 
genomic RNA from subgenomic RNA of each recombinant SFV replicon, a probe 
against the nsP4 region of SFV was PCR amplified and cloned into a pGEM vector. 
Each probe was prepared by in vitro transcription and labeled by random priming with 
32P. Specific interaction of each probe with the target gene was examined by northern 
blot analysis using in vitro transcribed recombinant SFV replicons and total cellular 
RNA extracted from IBV infected Vero cells. The highly specific interaction of these 
probes with the target genes was confirmed. The probe against nsP4 showed small 
amount of non-specific interaction compared to the other two probes. 
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Recombinant Replicons can be Packaged into IBV Virions 
Each replicon was in vitro transcribed using SP6 RNA polymerase following the 
manufacture’s instructions, precipitated with isopropyl alcohol and resuspended in 
DEPC treated water. Before transfection, the concentration of each replicon was 
quantified with spectrophotometer at OD260 and denaturing gel electrophoresis was used 
to confirm the size of each replicon. The overall experimental procedure is illustrated in 
Figure 23. Vero cells were infected with IBV Beaudette helper virus at 2 PFU per cell in 
order to provide virion structural proteins. One hour after infection, each replicon was 
transfected with DMRIE-C reagent (Invitrogen). Four hours after transfection, the media 
was replaced with complete DMEM media containing 10% FBS. Vero cells showed 
extensive syncytia formation 16 hours after infection. The supernatants were harvested 
and frozen before passaging to new Vero cells and the RNA from the cells was harvested 
for northern blot analysis using TRIZOL reagent. Passage 0 cellular RNAs were used to 
confirm the replication and transcription of replicons by northern blot analysis. To verify 
whether the replicons could be packaged into IBV virions, we passaged the supernatant 
into fresh susceptible cells instead of identifying the virion RNA from the supernatants 
after transfection. If the replicon could be packaged into virions, expression of EGFP 
could be detected using UV microscopy at Passage 1. IBV helper virus that supplied the 
structural proteins of IBV was inoculated into Vero cells before the transfection of the 
replicons. The total cellular RNA profile was analyzed by northern blot assays from 
passage 0 and PASSAGE 1. In multiple experiments, we found that every replicon could 
be passaged from passage 0 into passage 1 
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Infection of helper virus 
- Northern blot analysis
- Confirm expression of
   GFP 
FIG. 23. Schematic of the overall experimental design. 
In vitro transcription 
of Recombinant SFV 
replicons 
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Transfection of the transcripts
Total cellular RNA extraction
Construction 
of replicons 
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Figure 24. shows the northern blot analysis of the total cellular RNAs of passage 1 
transfected with pSFGFP and pSFGPS. A probe against EGFP can detect the genomic 
and subgenomic RNAs of replicons (Figure 24). Lanes 2 and 4 were used as controls 
that didn’t have packaging signal sequences in the construct. pSFGPS can be passaged 
into and replicates in passage 1 cells. These results show that not only the IBV virion can 
package recombinant SFV replicon without any cis signal sequence of IBV, but also the 
replicons can successfully infect and replicate in the infected cells. 
  
Packaging of the Recombinant SFV Replicons into IBV Virion is Helper Virus 
Dependent 
To determine whether packaging is truly helper virus dependant, we repeated the 
experiment with and without helper virus. As shown in Figure 25 in pictures B and D, 
only with helper virus infection the recombinant SFV replicon was transferred into new 
Vero cells and expressed EGFP in passage 1. To assure that this observation was not due 
to contamination of in vitro transcripts from passage 0, we treated passage 0 supernatant 
with RNaseA to remove possible residual RNA or RNA coating the outside of helper 
virions. As shown in Figure 24, there was no difference between RNase treatment and a 
control without RNase treatment. This suggests that the RNA is packaged inside of the  
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FIG. 24. Recombinant SFV replicons can be packaged into IBV virions with or 
without IBV cis sequences. Northern blot analysis of total cellular RNA of passage 1 
Vero cells infected with helper virus and then transfected with pSFGFP and pSFPS. A. 
Northern blot analysis using a probe specific to the IBV 3’ UTR to show each 
subgenomic RNA of IBV. Arrows indicate each subgenomic RNA of IBV. B. 
Northern blot analysis using a probe specific to the green fluorescent protein gene. 
The arrow heads indicates the genomic size of recombinant SFV replicons and arrow 
indicate subgenomic RNAs of replicons. C. Northern blot analysis using a probe 
against nsP4 gene of SFV. Odd numbers indicate the replicons containing putative 
packaging signal sequences and even numbers indicate the replicons without any IBV 
sequences. Lane 1 to 2, control, lane 3-4, treated with RNaseA, lane 5-6, treated with 
hyper immune serum against the IBV Beaudette strain from chickens, and lane 7-8, 
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A B
C D
FIG. 25. Without helper virus, recombinant SFV replicons cannot be passaged 
from passage 0 to passage 1. A and B are P0 and C and D are P1. A and C are the 
cells transfected with only pSFGFP constructs. B and D are the cells transfected 
with pSFGFP construct and infected with IBV Beaudette virus one hour post 
transfection. 
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virion or that RNA coating the outside of the virion can be protected from RNaseA 
digestion by virion protein. To verify whether the replicons are inside of the virion, we 
decided to remove the virion from the supernatant to see whether the replicon can be 
passaged into passage 1 from passage 0 without virion. To remove the virion from the 
supernatant, we utilized a neutralizing antibody against the helper virus to inhibit the 
infection of the helper virus and inhibit the carry over of recombinant SFV interacting 
with helper virion. To determine the amount of antibody that can completely neutralize 
the virus in the supernatant, a neutralization assay was performed. Only a 2-fold dilution 
of the antibody could completely neutralize the helper virus, therefore, this dilution was 
used to neutralize the passage 0 supernatant. After antibody treatment, no replicon was 
detected in passage 1 by Northern blot analysis nor was any helper virus replication as 
observed in Figure 24. 
 Surprisingly, replication of every replicon was detected even though the controls 
only have EGFP but no IBV sequences and no enhancement of packaging was observed 
in other recombinant SFVs containing packaging candidate sequences. It is concluded 
that packaging is more dependent on the concentration of transfectant than the presence 
of IBV sequences. With RNase treatment, the pSFGFP construct could still be passaged 
form passage 0 to passage 1. Based on this finding, we conclude that recombinant SFV 
replicons can be packaged into IBV virion even though we don’t know the mechanism 
of this packaging. 
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DISCUSSION 
 Viral RNA packaging mechanisms are comparatively well studied in plant 
viruses and retroviruses. It has been shown that the primary interaction of protein and 
RNA is important for viral RNA encapsidation and packaging into virions. In single 
stranded RNA viruses with icosahedral virions, it has been proposed that binding of 
structural proteins to a specific RNA structure forms an assembly initiation complex, 
which nucleates the subsequent addition of capsid protein subunits to complete a mature 
virion (80). For Tobacco mosaic virus (TMV), viral RNA interacts with the capsid 
protein and this interaction results in a polymer of helical ribonucelocapid complexes 
depending on the pH or other environmental factors and that the encapsidation process 
has been shown in vitro (29). For retroviruses, one protein, gag, is sufficient for virus 
particle assembly and is capable of specifically packaging the genomic RNA into 
particles (127). Without the packaging signal sequence that is referred as ψ, viral 
genomic packaging is significantly decreased. However, virions still contain non-viral 
RNA inside. Murjaux et al. (127) have shown that in Moloney murine leukemia virus 
(MMLV), viral RNA confers the stability of the virion. This study also reported an 
interesting observation. When the gag protein is expressed with SFV, the virus like 
particles package the SFV replicon inside of the virion. These study showed the 
possibility that RNA plays role as a structural component of virus and not only as a 
packaging signal sequence but also other unknown packaging. However, other unknown 
packaging mechanisms are important for viral RNA packaging. 
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Coronaviruses are largest known RNA virus containing from 27.6 to 31 kb of 
genomic RNA. It has been reported that TGEV have icosahedral cores inside of the viral 
envelope but this kind of internal core structure has not been shown in IBV (143). 
Because MHV produces subgenomic RNAs inside of infected cells and because of its 
specificity of genomic RNA packaging, it has been speculated that the packaging signal 
sequence of MHV might be located only in the genomic RNA region and not in 
subgenomic RNA.  
 However, it has been reported that IBV, BoCV and TGEV package some 
subgenomic RNA into their virion, in addition to genomic RNA (38, 204). The MHV 
packaging signal sequence was identified by studying DI by deletion mutation (124). It 
has been shown that the presence of the packaging signal sequence can confer the 
packaging of heterologous sequences into MHV virions (63). 
 The bovine coronavirus packaging signal sequence was identified by using 
sequence homologue searches (44). Cologna et al. found one region showing high 
sequence homology (~70%) with the MHV packaging signal sequence and went on to 
show that the presence of the packaging signal sequence conferred the specific 
packaging of foreign genes into BoCV virions (44, 63). One interesting point is that 
every DI that has the MHV packaging signal sequence can be packaged into MHV 
virions, but one of BoCV DI, Drep, that does not have the known BoCV packaging 
signal sequence, can still be packaged into BoCV virions (44). 
 We are interested in developing an efficient vaccine against IBV. One of the 
problems with IBV live vaccine development is its high rate of recombination and 
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frequent mutations caused by the lack of proofreading of the RdRp. Attenuated live 
vaccines, therefore, sometimes evolve into a new recombinant variant increasing the 
viral gene pool in field strains. To reduce the possible homologous recombination 
between vaccine strains and field strains, we proposed to express IBV proteins using 
other viral vectors in order to induce the cellular and humoral immunity against IBV. 
One of the candidates was the SFV vector. SFV eukaryotic expression vector has been 
known to be an efficient eukaryotic expression vector because of its promiscuous cell 
tropism and high expression of recombinant proteins. To engineer the SFV for an IBV 
vaccine, we wanted to use the IBV virion as a transfer vehicle for specifically targeting 
to the organs affected by IBV. To package the recombinant SFV into an IBV virion, 
identification of the packaging mechanism or packaging signal sequence is a 
prerequisite. Location of the packaging signal sequence of IBV was a focus of this work. 
Because previous reports indicated that the IBV virion packages not only genomic RNA 
but also packages varying amounts of subgenomic RNA depending on the virus strain, 
we proposed that IBV may have a different packaging mechanism from MHV. IBV 
might have more than one packaging signal sequence to allow packaging of both 
subgenomic and genomic RNA. We identified four different candidate packaging signal 
sequences. These sequences are located in the 3’ and 5’ untranslated regions, the ORF1b 
region in one DI of IBV that is efficient packaged into the virion and the one located by 
a sequence homology search with BoCV packaging sequence. 
As explained previously, the packaging signal sequence of IBV could not be 
identified using a recombinant SFV replicon. From our study, however, an interesting 
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finding is that rSFV replicons can be packaged into IBV virions in a concentration 
dependent manner. The exact mechanism of rSFV replicon packaging into the IBV 
virion is unknown. There is no significant sequence homology between the IBV and 
SFV genomes, but the putative packaging signal sequence may share a secondary 
structure. It is a possibility that, like retroviruses, coronaviruses need RNA to stabilize 
the RNP structure in order to facilitate the viral assembly process. This possibility is 
supported by the observation that N proteins interact with viral RNA producing RNP and 
that the protein has a high affinity to RNA. In MHV, Makino et al. (128) proposed that 
contrary to icosahedral virus packaging mechanisms, which utilize capsid protein 
interaction with viral RNA, integral membrane protein and packaging signal sequence 
interaction confer the specificity of genomic RNA packaging in MHV. M proteins have 
also been shown to interact with viral RNA.  
It is possible that one of the candidates we have identified is the packaging signal 
sequence even though significant differences in packaging efficiency of each 
recombinant replicon was not seen. In retroviruses, it has been shown that not only the 
packaging signal sequence itself, but also neighboring sequences significantly increase 
the packaging efficiency. It is also possible that the putative packaging signal sequence 
in SFV may have changed its secondary structure, such that the SFV RNA buries the 
packaging sequence. Because every candidate sequence was located down stream of 
EGFP, the location of the packaging signal may be important for efficient packaging and 
does not solely rely on the secondary structure of the packaging signal sequence. It is 
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also possible that IBV may need the cooperation of more than one packaging signal 
sequences.  
Alternatively, in addition to using packaging signal sequence for packaging, 
other packaging mechanisms have been reported. It is noteworthy that Cavangh’s group 
tried to identify the cis signal sequence necessary for viral RNA packaging using 
deletion mutations with IBV (48). Although this approach has not identified definitive 
sequences, it has been successful in understanding the cis signal sequences necessary for 
viral replication and transcription. 
Because of the availability of infectious cDNA clones of coronaviruses, it will be 
interesting to see whether the recombinant infectious cDNA having deletions in known 
packaging signal sequences of coronaviruses such as MHV, BoCV and TGEV can be 
packaged into virions. The infectious cDNA clone could further elucidate the packaging 
mechanisms of IBV. 
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CHAPTER V 
 
CONCLUSION 
 
Recently, there has been an escalation of interest in coronaviruses because of 
recent outbreak of severe acute respiratory syndrome (SARS) caused by a coronavirus 
now referred to as SCoV. However, coronavirus infection is a well known problem 
causing severe illness in infected animals from laboratory animals to agricultural animals 
including swine, cattle and poultry subsequently causing severe economic losses in 
agricultural industry. Avian infectious bronchitis is one of the oldest known diseases 
caused by the coronavirus, infectious bronchitis virus. 
A major focus of my efforts has been to develop an effective vaccine against 
IBV. Knowing the mechanism of viral pathogenesis is the prerequisite of developing 
effective methods to control viral infection. Infectious cDNA clones are the most useful 
tools to study the viral replication and pathogenesis. Several groups have been successful 
in constructing infectious cDNA clones of coronaviruses in the past three years. Three 
different approaches have been used for construction of infectious cDNA clones of 
coronaviruses. To overcome the cloning size limitation of plasmid vector, two vector 
systems were used which included bacterial artificial chromosome (BAC) for the 
construction of infectious cDNA of transmissible gastroenteritis virus (TGEV) and 
vaccinia virus for the infectious cDNA clones of infectious bronchitis virus (IBV) and 
human coronavirus (HCoV) (2, 31, 185). The third approach is an in vitro assembly 
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strategy. Instead of cloning the entire viral genome into a cloning vector, in vitro 
assembled DNA templates are used to transcribe full-length RNA transcripts using T7 
RNA polymerase (201, 202). By using this approach, infectious cDNA clones of MHV 
and TGEV have been constructed.  
Although, IBV infectious cDNA clones have been constructed using vaccinia 
virus as a cloning vector (31), the vaccinia system is time consuming because of its 
selection process for the recombinant vaccinia virus containing infectious cDNA clones 
of coronaviruses, and it is cumbersome to manipulate the recombinant vaccinia vector 
for producing mutations in coronavirus genes inside of vaccinia virus. Casai et al. (30) 
mentioned that they were not able to rescue infectious cDNA clones of IBV using the in 
vitro assembly technique. However, in our study we showed that construction of an 
infectious cDNA clone of IBV using an in vitro assembly strategy is possible.  
Several subsequent publications suggest that not only the infectious cDNA of 
coronaviruses can be used to study the molecular biology of the virus itself, but also can 
be used as a gene transfer vector or expression vector. One recent report also exploited 
the coronavirus to demonstrate that coronaviruses can be valuable candidates for a 
multigene transfer or making expression vectors because of their ability to produce 
multiple subgenomic RNA. Using more than two different promoters, proteins can be 
co-expressed without the interruption from other transcription unit that is inherent in 
some other expression vectors (187).  
To show the potential for using infectious cDNA clones of IBV as a gene transfer 
vector, I constructed a recombinant cDNA clone of IBV with the enhanced green 
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fluorescent protein (EGFP) gene. Compared to other coronaviruses, the IBV genome is 
compact and several ORFs overlap. However, IBV has several small ORFs known as 
group specific proteins whose functions are not well understood. Based on work with 
MHV, it is possible that these gene products are not necessary for viral survival in vitro. 
In this study, we replaced ORF5a with EGFP and the recombinant virus was viable and 
expressed EGFP in the virus infected cells. This showed the possibility that other group 
specific proteins may not be necessary for the viral survival at least in vitro.  
One of the problems with IBV live vaccine development is its high rate of 
recombination and frequent mutations, likely caused by the lack of the proofreading 
ability of the RdRp. Attenuated live vaccines sometimes evolve into a new recombinant 
variants, increasing the viral gene pool in field situations. To reduce the possible 
homologous recombination between vaccine strains and field strains, we proposed using 
other viral vectors to express the IBV S protein that can induce both cellular and 
humoral immunity against IBV. One of the candidates was SFV vector. SFV eukaryotic 
expression vector is an efficient eukaryotic expression vector because of its promiscuous 
cell tropism and high expression of recombinant proteins. To engineer SFV for an IBV 
vaccine, we wanted to use the IBV virion as a transfer vehicle that can be specifically 
targeted to the organs affected by IBV. To package the recombinant SFV into an IBV 
virion, identification of the packaging mechanism or packaging signal sequence is a 
prerequisite. Location of the packaging signal sequence of IBV was a focus of the work. 
Because previous reports indicated that the IBV virion packages not only genomic RNA 
but also packages varying amounts of subgenomic RNA depending on the virus strain, 
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we proposed that IBV may have a different packaging mechanism from MHV. IBV 
might have more than one packaging signal sequence that could be located in both 
subgenomic and genomic RNA. We identified four different candidate packaging signal 
sequences. These sequences are located in the 3’ and 5’ untranslated regions, the ORF1b 
region in one DI of IBV that is efficiently packaged into the virion and the one located 
by a sequence homology search with the BoCV packaging sequence. 
As explained previously, the packaging signal sequence of IBV could not be 
identified using a recombinant SFV replicon, however, an interesting finding of our 
studies is that rSFV replicons can be packaged into IBV virions in a concentration 
dependent manner. The exact mechanism of rSFV replicon packaging into the IBV 
virion is unknown. There is no significant sequence homology between the IBV and 
SFV genomes but the putative packaging signal sequence may share a secondary 
structure. It is a possibility that, like retroviruses, coronaviruses need RNA to stabilize 
the RNP structure facilitating the viral assembly process. This possibility is supported by 
the observation that N proteins interact with viral RNA producing RNP and that the 
protein has a high affinity for RNA. In MHV, Makino et al. proposed that contrary to 
icosahedral virus packaging mechanisms, which utilize capsid protein interaction with 
viral RNA, integral membrane protein and the packaging signal sequence interaction 
confer the specificity of genomic RNA packaging in MHV. M proteins have also been 
shown to interact with viral RNA.  
Because we now have infectious cDNA clones of coronaviruses, it will be 
interesting to see whether the recombinant infectious cDNA having deletions in known 
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packaging signal sequences of coronaviruses such as MHV, BoCV and TGEV can be 
packaged into virions. In addition, the infectious cDNA clone constructed in our 
laboratory could be a better tool for the study of the packaging mechanisms of IBV. 
In summary, an infectious cDNA clone originating from the Vero cell adapted 
Beaudette strain of IBV was constructed using the in vitro assembly technique. This 
cDNA clone was used to construct a recombinant infectious cDNA clone of IBV 
expressing EGFP. ORF5a was replaced with EGFP and this also showed that ORF5a is 
not necessary for the viral survival. The recombinant SFV vector system was used to 
identify the packaging signal sequence of IBV using four candidate IBV cis acting signal 
sequences. A specific packaging signal sequence was not found in any of the candidate 
signal sequences, however, it has been shown that SFV can be packaged into IBV virion 
without any IBV cis acting signal sequence showing the possibility of using SFV for the 
construction of chimeric SFV-IBV vector for vaccine development in the absence of 
IBV specific packaging signal sequences. 
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